



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:		(11) International Publication Number: WO 99/07701
C07D 403/02, 413/02, 411/02, 419/02, 417/02, A61K 31/495	A1	(43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/US98/16232		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIGO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 4 August 1998 (04.08.98)		
(30) Priority Data: 60/054,903 5 August 1997 (05.08.97) US 60/059,686 19 September 1997 (19.09.97) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIGO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant: SUGEN, INC. [US/US]; 351 Galveston Drive, Redwood City, CA 94063 (US).		Published <i>With international search report.</i> <i>With amended claims.</i>
(72) Inventors: TANG, Peng, Cho; 827 Camino Ricardo, Moraga, CA 94556 (US). McMAHON, Gerald; 1800 Schultz Road, Kenwood, CA 95452 (US).		
(74) Agents: ROSE, Bernard, F. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).		

(54) Title: TRICYCLIC QUINOXALINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS

(57) Abstract

The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION

TRICYCLIC QUINOXALINE DERIVATIVES AS PROTEIN TYROSINE KINASE

5 INHIBITORS

RELATED APPLICATIONS

This application is related to and claims priority from provisional application serial number 60/054,903, dated August 10 4, 1997, and provisional application serial number 60/259,686, dated September 19, 1997, both of which are incorporated by reference as if fully set forth herein.

INTRODUCTION

15

The present invention relates generally to organic chemistry, biochemistry, pharmacology and medicine. More particularly, it relates to tricyclic quinoxaline compounds, and their physiologically acceptable salts and prodrugs, which 20 modulate the activity of protein tyrosine kinases ("PTKs") and, therefore, are expected to exhibit a salutary effect against disorders related to abnormal PTK activity.

BACKGROUND OF THE INVENTION

The following is offered as background information only and is not admitted to be prior art to the present invention.

5 Protein kinases, PKs, are enzymes that catalyze the phosphorylation of hydroxy groups on tyrosine, serine and threonine residues of proteins. The consequences of this seemingly simple activity are staggering; cell growth, differentiation and proliferation; i.e., virtually all aspects
10 of cell life in one way or another depend on PK activity. Furthermore, abnormal PK activity has been related to a host of disorders, ranging from relatively non-life threatening diseases such as psoriasis to extremely virulent diseases such as glioblastoma (brain cancer).

15 The PKs can conveniently be broken down into two classes, the protein tyrosine kinases (PTKs) and the serine-threonine kinases (STKs).

One of the prime aspects of PK activity is involvement with growth factor receptors. Growth factor receptors are cell-
20 surface proteins. When bound by a growth factor ligand, growth factor receptors are converted to an active form which interacts with proteins on the inner surface of a cell membrane. This leads to phosphorylation on tyrosine residues of the receptor and other proteins and to the formation inside the cell of complexes with a variety of cytoplasmic signaling
25 molecules that, in turn, affect numerous cellular responses

such as cell division (proliferation), cell differentiation, cell growth, expression of metabolic effects on the extracellular microenvironment, etc. For a more complete discussion, see Schlessinger and Ullrich, Neuron, 9:303-391 5 (1992) which is incorporated by reference, including any drawings, as if fully set forth herein.

Growth factor receptors with PK activity are known as receptor tyrosine kinases ("RTKs"). They comprise a large family of transmembrane receptors with diverse biological 10 activity. At present, at least nineteen (19) distinct subfamilies of RTKs have been identified. An example of these is the subfamily designated the "HER" RTKs, which include EGFR (epithelial growth factor receptor), HER2, HER3 and HER4. These RTKs consist of an extracellular glycosylated ligand 15 binding domain, a transmembrane domain and an intracellular cytoplasmic catalytic domain that can phosphorylate tyrosine residues on proteins.

Another RTK subfamily consists of insulin receptor (IR), insulin-like growth factor I receptor (IGF-1R) and the insulin 20 receptor related receptor (IRR). IR and IGF-1R interact with insulin, IGF-I and IGF-II to form a heterotetramer of two entirely extracellular glycosylated α subunits and two β subunits which cross the cell membrane and which contain the tyrosine kinase domain.

25 A third RTK subfamily is referred to as the platelet derived growth factor receptor ("PDGFR") group, which includes

PDGFR α , PDGFR β , CSFIR, c-kit and c-fms. These receptors consist of glycosylated extracellular domains composed of variable numbers of immunoglobulin-like loops and an intracellular domain wherein the tyrosine kinase domain is 5 interrupted by unrelated amino acid sequences.

Another group which, because of its similarity to the PDGFR subfamily, is sometimes subsumed in the latter group is the fetus liver kinase ("flk") receptor subfamily. This group is believed to be composed of kinase insert domain-receptor 10 fetal liver kinase-1 (KDR/FLK-1), flk-1R, flk-4 and fms-like tyrosine kinase 1 (flt-1).

One further member of the tyrosine kinase growth factor receptor family is the fibroblast growth factor ("FGF") receptor group. This group consists of four receptors, FGFR1-4, and 15 seven ligands, FGF1-7. While not yet well characterized, it appears that the receptors consist of a glycosylated extracellular domain containing a variable number of immunoglobulin-like loops and an intracellular domain in which the PTK sequence is interrupted by regions of unrelated amino 20 acid sequences.

A more complete listing of the known RTK subfamilies is described in Plowman et al., DN&P, 7(6):334-339 (1994) which is incorporated by reference, including any drawings, as if fully set forth herein.

25 In addition to the RTKs, there also exists a family of entirely intracellular PTKs called "non-receptor tyrosine

kinases" or "cellular tyrosine kinases." This latter designation, abbreviated "CTK", will be used herein. CTKs do not contain extracellular and transmembrane domains. At present, over 24 CTKs in 11 subfamilies (Src, Frk, Btk, Csk, 5 Abl, Zap70, Fes, Fps, Fak, Jak and Ack) have been identified. The Src subfamily appear so far to be the largest group of CTKs and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. For a more detailed discussion of CTKs, see Bolen, Oncogene, 8:2025-2031 (1993), which is incorporated by reference, 10 including any drawings, as if fully set forth herein.

The serine-threonine kinases or STKs, like the CTKs, are predominantly intracellular although there are a few receptor STKs. STKs are the most common of the cytosolic kinases; i.e., kinases which perform their function in that part of the 15 cytoplasm other than the cytoplasmic organelles and cytoskelton. The cytosol is the region within the cell where much of the cell's intermediary metabolic and biosynthetic activity occurs; e.g., it is in the cytosol that proteins are synthesized on ribosomes.

20 RTKs, CTKs and STKs have all been implicated in a host of pathogenic conditions including, significantly, cancer. Others pathogenic conditions which have been associated with PTKs include, without limitation, psoriasis, hepatic cirrhosis, diabetes, atherosclerosis, angiogenesis, restenosis, ocular 25 diseases, rheumatoid arthritis and other inflammatory disorders, autoimmune disease and a variety of renal disorders.

With regard to cancer, two of the major hypotheses advanced to explain the excessive cellular proliferation that drives tumor development relate to functions known to be PK regulated. That is, it has been suggested that malignant cell 5 growth results from a breakdown in the mechanisms that control cell division and/or differentiation. It has been shown that the protein products of a number of proto-oncogenes are involved in the signal transduction pathways that regulate cell growth and differentiation. These protein products of proto- 10 oncogenes include the extracellular growth factors, transmembrane growth factor PTK receptors (RTKs), cytoplasmic PTKs (CTKs) and cytosolic STKs, discussed above.

In view of the apparent link between PK-related cellular activities and a number of human disorders, it is no surprise 15 that a great deal of effort is being spent in an attempt to identify ways to modulate PK activity. Some of these efforts have involved biomimetic approaches using large molecules patterned after those involved in the actual cellular processes (e.g., mutant ligands (U.S. App. No. 4,966,849); soluble 20 receptors and antibodies (App. No. WO 94/10202, Kendall and Thomas, Proc. Nat'l Acad. Sci., 90:10705-09 (1994), Kim, et al., Nature, 362:841-844 (1993)); RNA ligands (Jelinek, et al., Biochemistry, 33:10450-56); Takano, et al., Mol. Bio. Cell 25 4:358A (1993); Kinsella, et al., Exp. Cell Res. 199:56-62 (1992); Wright, et al., J. Cellular Phys., 152:448-57) and tyrosine kinase inhibitors (WO 94/03427; WO 92/21660; WO

91/15495; WO 94/14808; U.S. Pat. No. 5,330,992; Mariani, et al., Proc. Am. Assoc. Cancer Res., 35:2268 (1994)).

More recently, attempts have been made to identify small molecules which act as PK inhibitors. For example, bis-5 monocyclic, bicyclic and heterocyclic aryl compounds (PCT WO 92/20642), vinylene-azaindole derivatives (PCT WO 94/14808) and 1-cyclopropyl-4-pyridylquinolones (U.S. Pat. No. 5,330,992) have been described as PTK inhibitors. Styryl compounds (U.S. Pat. No. 5,217,999), styryl-substituted pyridyl compounds (U.S. 10 Pat. No. 5,302,606), quinazoline derivatives (EP App. No. 0 566 266 A1), selenaindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660) and benzylphosphonic acid compounds (PCT WO 91/15495) have all been described as PTK inhibitors useful in the treatment of cancer.

15

SUMMARY OF THE INVENTION

Our own efforts to identify small organic molecules which modulate PK activity and which, therefore, would be expected to be useful in the treatment or prevention of disorders driven by 20 abnormal PK activity, has led us to the discovery of a family of tricyclic quinoxaline compounds which exhibit such PK-modulating activity and which are the subject of this invention.

Thus, the present invention relates generally to tricyclic 25 quinoxaline derivatives which modulate the activity of both receptor (RTK) and non-receptor (CTK) protein tyrosine kinases

(PTKs). In addition, the present invention relates to the preparation and use of pharmacological compositions of the disclosed compounds and their physiologically acceptable salts and prodrugs in the treatment or prevention of PTK driven disorders such as, by way of example and not limitation, cancer, diabetes, hepatic cirrhosis, atherosclerosis, angiogenesis and renal disease.

As used herein a "tricyclic quinoxaline derivative" refers to a chemical compound having the general structure shown in 10 Formula 1.

A "pharmacological composition" refers to a mixture of one or more of the compounds described herein, or physiologically acceptable salts or prodrugs thereof, with other chemical components such as physiologically acceptable carriers and 15 excipients. The purpose of a pharmacological composition is to facilitate administration of a compound to an organism.

A "prodrug" refers to an agent which is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the 20 parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility compared to the parent drug in pharmacological compositions. An example, without limitation, of a prodrug would be a compound of the present invention which 25 is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is

not beneficial, but which then is metabolically hydrolyzed to the carboxylic acid once inside the cell where water solubility is beneficial.

As used herein, an "ester" is a carboxy group, as defined herein, wherein R" is any of the listed groups other than 5 hydrogen.


As used herein, a "physiologically acceptable carrier" refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological 10 activity and properties of the administered compound.

An "excipient" refers to an inert substance added to a pharmacological composition to further facilitate administration of a compound. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, 15 various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

1. THE COMPOUNDS

A. General Structural Features.

In one aspect, the present invention relates to compounds 20 having the structure shown in Formula 1:



The dotted line in the five-member ring containing A, B and D means that either the A-B bond or the B-D bond is a double bond.

A, B, and D are independently selected from the group 5 consisting of carbon, nitrogen, oxygen and sulfur, such that the resulting fused 5-member ring/6-member ring is one known in the chemical arts. It is understood that when A, B or D is oxygen or sulfur, R¹, R² and R³, respectively, do not exist. Furthermore, when A, B or D is nitrogen and that nitrogen is 10 participating in a double bond, R¹, R² or R³, respectively, does not exist.

When A, B or D is nitrogen and that nitrogen is not participating in a double bond, R¹, R² or R³ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, 15 cycloalkyl, aryl, hydroxy, alkoxy, C-carboxy, O-carboxy, carbonyl, thiocarbonyl, C-amido, guanyl, sulfonyl and trihalomethylsulfonyl.


R⁴, R⁵, R⁶ and R⁷ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, 20 alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, N-sulfonamido, S-sulfonamido, trihalomethane-sulfonamido, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-carbamyl, N-25 carbamyl, O-thiocarbamyl, N-thiocarbamyl, ureido, guanyl, guanidino, amino, and -NR¹⁰R¹¹, with the proviso that, when one

of R⁵ or R⁶ is hydrogen, methyl or phenyl, the other is not any of hydrogen, methyl or phenyl.

R¹⁰ and R¹¹ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, 5 sulfonyl and, combined, a five- or six-member heteroalicyclic ring.

Physiologically acceptable salts and prodrugs of the claimed compounds are also within the scope of this invention.

Examples of a "fused 5-member ring/6-member ring known in 10 the chemical arts" include, but are not limited to:



As used herein, to "participate in a double bond" means to be one of two atoms which are double-bonded to one another.

15 As used herein, the term "alkyl" refers to a saturated aliphatic hydrocarbon including straight chain and branched chain groups. Preferably, the alkyl group has 1 to 20 carbon

atoms (whenever a numerical range; e.g. "1-20", is stated herein, it means that the group, in this case the alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. up to and including 20 carbon atoms). More preferably, it is a 5 medium size alkyl having 1 to 10 carbon atoms. Most preferably, it is a lower alkyl having 1 to 4 carbon atoms. The alkyl group may be substituted or unsubstituted. When substituted, the substituent group is preferably one or more independently selected from cycloalkyl, aryl, heteroaryl, 10 heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, nitro, sulfonamido, trihalomethanesulfonamido, silyl, guanyl, guanidino, ureido, 15 amino and NR¹⁰R¹¹, wherein R¹⁰ and R¹¹ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, sulfonyl, trihalomethysulfonyl and, combined, a five- or six-member heteroalicyclic ring.

A "cycloalkyl" group refers to an all-carbon monocyclic or 20 fused ring (i.e., rings which share an adjacent pair of carbon atoms) group wherein one of more of the rings does not have a completely conjugated pi-electron system. Examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, 25 cycloheptane, cycloheptatriene and adamantane. A cycloalkyl group may be substituted or unsubstituted. When substituted,

the substituent group(s) is preferably one or more independently selected from alkyl, aryl, heteroaryl, heteroalycyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, halo, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, O- 5 carbamyl, N-carbamyl, C-amido, N-amido, nitro, amino and $NR^{10}R^{11}$, with R^{10} and R^{11} being as defined above.

An "alkenyl" group refers to an alkyl group which consists of at least two carbon atoms and at least one carbon-carbon double bond.

10 An "alkynyl" group refers to an alkyl group which consists of at least two carbon atoms and at least one carbon-carbon triple bond.

An "aryl" group refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs 15 of carbon atoms) groups having a completely conjugated pi-electron system. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. The aryl group may be substituted or unsubstituted. When substituted, the substituent group is preferably one or more selected from halo, 20 trihalomethyl, alkyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, nitro, azido, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, sulfinyl, sulfonyl, amino and $NR^{10}R^{11}$ wherein R^{10} and R^{11} are previously 25 defined herein.

As used herein, a "heteroaryl" group refers to a

monocyclic or fused ring (i.e., rings which share an adjacent pair of atoms) group having in the ring(s) one or more atoms selected from the group consisting of nitrogen, oxygen and sulfur and, in addition, having a completely conjugated pi-electron system. Examples, without limitation, of heteroaryl groups are pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline and purine. The heteroaryl group may be substituted or unsubstituted. When substituted, the substituted group is preferably one or more selected from alkyl, cycloalkyl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, azido, nitro, carbonyl, thiocarbonyl, sulfonamido, C-carboxy, O-carboxy, sulfinyl, sulfonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino and $NR^{10}R^{11}$ where R^{10} and R^{11} are previously defined herein.

A "heteroalicyclic" group refers to a monocyclic or fused ring group having in the ring(s) one or more atoms selected from the group consisting of nitrogen, oxygen and sulfur. The rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system. The heteroalicyclic ring may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more selected from alkyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, nitro, carbonyl, thiocarbonyl,

C-carboxy, O-carboxy, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, sulfinyl, sulfonyl, C-amido, N-amido, amino and NR¹⁰R¹¹ where R¹⁰ and R¹¹ are previously defined herein.

A "hydroxy" group refers to an -OH group.

5 An "azido" group refers to a -N≡N group.

An "alkoxy" group refers to both an -O-alkyl and an -O-cycloalkyl group, as defined herein.

An "aryloxy" group refers to both an -O-aryl and an -O-heteroaryl group, as defined herein.

10 A "thiohydroxy" group refers to an -SH group.

A "thioalkoxy" group refers to both an S-alkyl and an -S-cycloalkyl group, as defined herein.

A "thioaryloxy" group refers to both an -S-aryl and an -S-heteroaryl group, as defined herein.

15 A "carbonyl" group refers to a -C(=O)-R" group, where R" is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), as defined herein.

20 An "aldehyde" group refers to a carbonyl group where R" is hydrogen.

A "thiocarbonyl" group refers to a -C(=S)-R" group, with R" as defined herein.

25 A "C-carboxy" group refers to a -C(=O)O-R" groups, with R" as defined herein.

An "O-carboxy" group refers to a R"C(=O)O- group, with R"

as defined herein.

A "carboxylic acid" group refers to a C-carboxyl group in which R" is hydrogen.

5 A "halo" group refers to fluorine, chlorine, bromine or iodine.

A "trihalomethyl" group refers to a -CX₃ group wherein X is a halo group as defined herein.

A "trihalomethanesulfonyl" group refers to a X₃CS(=O)₂- groups with X as defined above.

10 A "sulfinyl" group refers to a -S(=O)-R" group, with R" as defined herein.

A "sulfonyl" group refers to a -S(=O)₂R" group, with R" as defined herein.

An "S-sulfonamido" group refers to a -S(=O)₂NR¹⁰R¹¹ group, 15 with R¹⁰ and R¹¹ as defined herein.

An "N-sulfonamido" group refers to a R¹⁰(=O)₂NR¹¹- group, with R¹⁰ and R¹¹ as defined herein.

A "trihalomethanesulfonamido" group refers to a X₃CS(=O)₂NR¹⁰- group with R¹⁰ as defined herein.

20 An "O-carbamyl" group refers to a -OC(=O)NR¹⁰R¹¹ group with R¹⁰ and R¹¹ as defined herein.

An "N-carbamyl" group refers to a R¹¹OC(=O)NR¹⁰- group, with R¹⁰ and R¹¹ as defined herein.

An "O-thiocarbamyl" group refers to a -OC(=S)NR¹⁰R¹¹ group 25 with R¹⁰ and R¹¹ as defined herein.

An "N-thiocarbamyl" group refers to a R¹¹OC(=S)NR¹⁰- group,

with R¹⁰ and R¹¹ as defined herein.

An "amino" group refers to an -NH₂ group.

A "C-amido" group refers to a -C(=O)NR¹⁰R¹¹ group with R¹⁰ and R¹¹ as defined herein.

5 An "N-amido" group refers to a R¹¹C(=O)NR¹⁰- group, with R¹⁰ and R¹¹ as defined herein.

A "quaternary ammonium" group refers to a -NHR¹⁰R¹¹ group wherein R¹⁰ and R¹¹ are independently selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl.

10 A "ureido" group refers to a -NR¹⁰C(=O)NR¹¹R¹² group, with R¹⁰ and R¹¹ as defined herein and R¹² defined the same as R¹⁰ and R¹¹.

A "guanidino" group refers to a -R¹⁰NC(=N)NR¹¹R¹² group, with R¹⁰, R¹¹ and R¹² as defined herein.

15 A "guanyl" group refers to a R¹⁰R¹¹NC(=N)- group, with R¹⁰ and R¹¹ as defined herein.

A "nitro" group refers to a -NO₂ group.

A "cyano" group refers to a -C≡N group.

A "silyl" group refers to a -Si(R")₃, with R" as defined herein.

20 **B. Preferred Structural Features.**

Preferred structural features of this invention are those in which:

A and D are nitrogen, B is carbon and either A or D is participating in a double bond.

25 The "R" group bonded to whichever of A or D is not participating in a double bond; i.e., R¹ or R³, is selected from

the group consisting of hydrogen, alkyl, halo, cycloalkyl, aryl, carbonyl and C-carboxy.

R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl, trihalomethyl, aryl, hydroxy, alkoxy, 5 aryloxy, O-carboxy, amino and NR¹⁰R¹¹ where R¹⁰ and R¹¹ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, sulfonyl, trihalomethanesulfonyl and, combined, a five- or six-member heteroalicyclic ring.

10 R⁴ and R⁷ are independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryloxy, C-carboxy, cycloalkyl, hydroxy and halo.

R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxy, aryl, 15 aryloxy, heteroaryl, heteroalicyclic, hydroxy and halo with the proviso that, when one of R⁵ or R⁶ is hydrogen, methyl or phenyl, the other is not any of hydrogen, methyl or phenyl.

Further preferred embodiments of this invention are those in which:

20 A is nitrogen which is participating in a double bond.

D is sulfur.

R², R⁴ and R⁷ are independently selected from the group consisting of hydrogen, alkyl and cycloalkyl.

R⁵ and R⁶ are independently selected from the group 25 consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy and aryloxy.

Additional preferred embodiments of this invention are those in which:

A is sulfur.

5 B and D are carbon atoms which are participating in a double bond.

R² and R³ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, C-carboxy and C-amido.

10 R⁴ and R⁷ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, aryloxy and carbonyl.

R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl and 15 heteroalicyclic with the proviso that, when one of R⁵ or R⁶ is hydrogen, methyl or phenyl, the other is not any of hydrogen, methyl or phenyl.

The compounds shown in Table 1, infra, comprise still further preferred embodiments of this invention. The 20 substituent designations refer to Formula 1, supra.

TABLE 1

Compound No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
1	N	C	N	-CH ₃	CH ₃	-	H	p-CH ₃ Ph	H	H
2	N	C	N	CH ₃	CH ₃	-	H	p-CH ₃ OPh	H	H
3	N	C	N	CH ₃	CH ₃	-	H	p-HOPh	H	H
4	N	C	N	CH ₃	CH ₃	-	H	p-(CH ₃) ₂ NPh	H	H
5	N	C	N	CH ₃	CH ₃	-	H	p-N ₃ Ph	H	H
6	N	C	N	CH ₃	CH ₃	-	H	furan	H	H
7	N	C	N	CH ₃	CH ₃	-	H	H	p-NO ₂ Ph	H
8	N	C	N	CH ₃	CH ₃	-	H	H	p-CH ₃ Ph	H
9	N	C	N	CH ₃	CH ₃	-	H	H	p-CH ₃ OPh	H
10	N	C	N	CH ₃	CH ₃	-	H	H	p-HOPh	H
11	N	C	N	CH ₃	CH ₃	-	H	H	p-(CH ₃) ₂ NPh	H
12	N	C	N	CH ₃	CH ₃	-	H	H	p-N ₃ Ph	H
13	N	C	N	CH ₃	CH ₃	-	H	H	furan	H
14	N	C	N	CH ₃	CH ₃	-	H	p-BrPh	p-BrPh	H
15	N	C	N	CH ₃	CH ₃	-	H	p-CH ₃ Ph	p-CH ₃ Ph	H
16	N	C	N	CH ₃	CH ₃	-	H	p-CH ₃ OPh	p-CH ₃ OPh	H
17	N	C	N	CH ₃	CH ₃	-	H	p-(CH ₃) ₂ NPh	p-(CH ₃) ₂ NPh	H
18	N	C	N	CH ₃	CH ₃	-	H	o-ClPh	o-ClPh	H
19	N	C	N	CH ₃	CH ₃	-	H	m-CH ₃ OPh	m-CH ₃ OPh	H
20	N	C	N	CH ₃	CH ₃	-	H	3-Br-6-OHPh	3-Br-6-OHPh	H
21	N	C	N	CH ₃	CH ₃	-	H	furan-2-yl	furan-2-yl	H
22	N	C	N	CH ₃	CH ₃	-	H	thiophene-2-yl	thiophene-2-yl	H
23	N	C	N	CH ₃	CH ₃	-	H	pyridine-2-yl	pyridine-2-yl	H
24	N	C	N	CH ₃	CH ₃	-	H	6-CH ₃ pyridine-2-yl	6-CH ₃ pyridine-2-yl	H
25	N	C	N	CH ₃	CH ₃	-	CH ₃	Ph	H	H
26	N	C	N	CH ₃	CH ₃	-	CH ₃	H	Ph	H
27	N	C	N	CH ₃	CH ₃	-	CH ₃	Ph	Ph	H
28	N	C	N	CH ₃	CH ₃	-	CH ₃	p-NO ₂ Ph	H	H
29	N	C	N	CH ₃	CH ₃	-	CH ₃	p-CH ₃ Ph	H	H
30	N	C	N	CH ₃	CH ₃	-	CH ₃	p-CH ₃ OPh	H	H
31	N	C	N	CH ₃	CH ₃	-	CH ₃	p-HOPh	H	H
32	N	C	N	CH ₃	CH ₃	-	CH ₃	p-(CH ₃) ₂ NPh	H	H

Compound No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
33	N	C	N	-CH ₃	CH ₃	-	CH ₃	p-N ₃ Ph	H	H
34	N	C	N	CH ₃	CH ₃	-	CH ₃	furan	H	H
35	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-N ₂ Ph	H
36	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-CH ₃ Ph	H
37	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-CH ₃ OPh	H
38	N	C	N	CH ₃	CH ₃	-	CH ₃	H	o-OHPh	H
39	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-(CH ₃) ₂ NPh	H
40	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-N ₃ Ph	H
41	N	C	N	CH ₃	CH ₃	-	CH ₃	H	furan	H
42	N	C	N	CH ₃	CH ₃	-	CH ₃	p-BrPh	p-BrPh	H
43	N	C	N	CH ₃	CH ₃	-	CH ₃	p-CH ₃ Ph	p-CH ₃ Ph	H
44	N	C	N	CH ₃	CH ₃	-	CH ₃	p-CH ₃ OPh	p-CH ₃ OPh	H
45	N	C	N	CH ₃	CH ₃	-	CH ₃	p-(CH ₃) ₂ NPh	p-(CH ₃) ₂ NPh	H
46	N	C	N	CH ₃	CH ₃	-	CH ₃	o-ClPh	o-ClPh	H
47	N	C	N	CH ₃	CH ₃	-	CH ₃	m-CH ₃ OPh	m-CH ₃ OPh	H
48	N	C	N	CH ₃	CH ₃	-	CH ₃	3-Br-6-OHPh	3-Br-6-OHPh	H
49	N	C	N	CH ₃	CH ₃	-	CH ₃	furan-2-yl	furan-2-yl	H
50	N	C	N	CH ₃	CH ₃	-	CH ₃	thiophene-2-yl	thiophene-2-yl	H
51	N	C	N	CH ₃	CH ₃	-	CH ₃	pyridine-2-yl	pyridine-2-yl	H
52	N	C	N	CH ₃	CH ₃	-	CH ₃	6-CH ₃ pyridine-2-yl	6-CH ₃ pyridine-2-yl	H
53	N	C	N	CH ₃	CH ₃	-	CH ₃	CH ₃	H	H
54	N	C	N	CH ₃	CH ₃	-	CH ₃	H	CH ₃	H
55	N	C	N	CH ₃	CH ₃	-	CH ₃	CH ₃	CH ₃	H
56	N	C	N	CH ₃	CH ₃	-	CH ₃	Ph	H	H
57	N	C	N	CH ₃	CH ₃	-	CH ₃	H	Ph	H
58	N	C	N	CH ₃	CH ₃	-	CH ₃	Ph	Ph	H
59	N	C	N	CH ₃	CH ₃	-	CH ₃	CH ₃	H	H
60	N	C	N	CH ₃	CH ₃	-	CH ₃	H	CH ₃	H
61	N	C	N	CH ₃	CH ₃	-	CH ₃	CH ₃	CH ₃	H
62	N	C	N	CH ₃	CH ₃	-	F	Ph	H	H
63	N	C	N	CH ₃	CH ₃	-	F	H	Ph	H
64	N	C	N	CH ₃	CH ₃	-	F	Ph	Ph	H

Compound No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
65	N	C	N	CH ₃	CH ₃	-	F	p-NO ₂ Ph	H	H
66	N	C	N	CH ₃	CH ₃	-	F	p-CH ₃ Ph	H	H
67	N	C	N	CH ₃	CH ₃	-	F	p-CH ₃ OPh	H	H
68	N	C	N	CH ₃	CH ₃	-	F	p-HOPh	H	H
69	N	C	N	CH ₃	CH ₃	-	F	p-(CH ₃) ₂ NPh	H	H
70	N	C	N	CH ₃	CH ₃	-	F	p-N ₃ Ph	H	H
71	N	C	N	CH ₃	CH ₃	-	F	furan	H	H
72	N	C	N	CH ₃	CH ₃	-	F	H	p-NO ₂ Ph	H
73	N	C	N	CH ₃	CH ₃	-	F	H	p-CH ₃ Ph	H
74	N	C	N	CH ₃	CH ₃	-	F	H	p-CH ₃ OPh	H
75	N	C	N	CH ₃	CH ₃	-	F	H	p-HOPh	H
76	N	C	N	CH ₃	CH ₃	-	F	H	p-(CH ₃) ₂ NPh	H
77	N	C	N	CH ₃	CH ₃	-	F	H	p-N ₃ Ph	H
78	N	C	N	CH ₃	CH ₃	-	F	H	furan	H
79	N	C	N	CH ₃	CH ₃	-	F	p-BrPh	p-BrPh	H
80	N	C	N	CH ₃	CH ₃	-	F	p-CH ₃ Ph	p-CH ₃ Ph	H
81	N	C	N	CH ₃	CH ₃	-	F	p-CH ₃ OPh	p-CH ₃ OPh	H
82	N	C	N	CH ₃	CH ₃	-	F	p-(CH ₃) ₂ NPh	p-(CH ₃) ₂ NPh	H
83	N	C	N	CH ₃	CH ₃	-	F	o-ClPh	o-ClPh	H
84	N	C	N	CH ₃	CH ₃	-	F	m-CH ₃ OPh	m-CH ₃ OPh	H
85	N	C	N	CH ₃	CH ₃	-	F	3-Br-6-OHPh	3-Br-6-OHPh	H
86	N	C	N	CH ₃	CH ₃	-	F	furan-2-yl	furan-2-yl	H
87	N	C	N	CH ₃	CH ₃	-	F	thiophene-2-yl	thiophene-2-yl	H
88	N	C	N	CH ₃	CH ₃	-	F	pyridine-2-yl	pyridine-2-yl	H
89	N	C	N	CH ₃	CH ₃	-	F	6-CH ₃ pyridine-2-yl	6-CH ₃ pyridine-2-yl	H
90	N	C	N	CH ₃	CH ₃	-	COOH	Ph	H	H
91	N	C	N	CH ₃	CH ₃	-	COOH	H	Ph	H
92	N	C	N	CH ₃	CH ₃	-	COOH	Ph	H	H
93	N	C	N	CH ₃	CH ₃	-	COOH	p-NO ₂ Ph	H	H
94	N	C	N	CH ₃	CH ₃	-	COOH	p-CH ₃ Ph	H	H
95	N	C	N	CH ₃	CH ₃	-	COOH	p-CH ₃ OPh	H	H
96	N	C	N	CH ₃	CH ₃	-	COOH	p-HOPh	H	H

Compound No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
97	N	C	N	CH ₃	CH ₃	-	COOH	p-(CH ₃) ₂ NPh	H	H
98	N	C	N	CH ₃	CH ₃	-	COOH	p-N ₃ Ph	H	H
99	N	C	N	CH ₃	CH ₃	-	COOH	furan	H	H
100	N	C	N	CH ₃	CH ₃	-	COOH	H	p-NO ₂ Ph	H
101	N	C	N	CH ₃	CH ₃	-	COOH	H	p-CH ₃ Ph	H
102	N	C	N	CH ₃	CH ₃	-	COOH	H	p-CH ₃ OPh	H
103	N	C	N	CH ₃	CH ₃	-	COOH	H	p-HOPh	H
104	N	C	N	CH ₃	CH ₃	-	COOH	H	p-(CH ₃) ₂ NPh	H
105	N	C	N	CH ₃	CH ₃	-	COOH	H	p-N ₃ Ph	H
106	N	C	N	CH ₃	CH ₃	-	COOH	H	furan	H
107	N	C	N	CH ₃	CH ₃	-	COOH	p-BrPh	p-BrPh	H
108	N	C	N	CH ₃	CH ₃	-	COOH	p-CH ₃ Ph	p-CH ₃ Ph	H
109	N	C	N	CH ₃	CH ₃	-	COOH	p-CH ₃ OPh	p-CH ₃ OPh	H
110	N	C	N	CH ₃	CH ₃	-	COOH	p-(CH ₃) ₂ NPh	p-(CH ₃) ₂ NPh	H
111	N	C	N	CH ₃	CH ₃	-	COOH	o-ClPh	o-ClPh	H
112	N	C	N	CH ₃	CH ₃	-	COOH	m-CH ₃ OPh	m-CH ₃ OPh	H
113	N	C	N	CH ₃	CH ₃	-	COOH	3-Br-6-OHPh	3-Br-6-OHPh	H
114	N	C	N	CH ₃	CH ₃	-	COOH	furan-2-yl	furan-2-yl	H
115	N	C	N	CH ₃	CH ₃	-	COOH	thiophene-2-yl	thiophene-2-yl	H
116	N	C	N	CH ₃	CH ₃	-	COOH	pyridine-2-yl	pyridine-2-yl	H
117	N	C	N	CH ₃	CH ₃	-	COOH	6-CH ₃ pyridine-2-yl	6-CH ₃ pyridine-2-yl	H
118	N	C	N	CH ₃	CH ₃	-	OCH ₃	Ph	H	H
119	N	C	N	CH ₃	CH ₃	-	OCH ₃	H	Ph	H
120	N	C	N	CH ₃	CH ₃	-	OCH ₃	Ph	Ph	H
121	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-NO ₂ Ph	H	H
122	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-CH ₃ Ph	H	H
123	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-CH ₃ OPh	H	H
124	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-HOPh	H	H
125	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-(CH ₃) ₂ NPh	H	H
126	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-N ₃ Ph	H	H
127	N	C	N	CH ₃	CH ₃	-	OCH ₃	furan	H	H

Compound No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
128	N	C	N	CH ₃	CH ₃	-	OCH ₃	H	p-NO ₂ Ph	H
129	N	C	N	CH ₃	CH ₃	-	OCH ₃	H	p-CH ₃ Ph	H
130	N	C	N	CH ₃	CH ₃	-	OCH ₃	H	p-CH ₃ OPh	H
131	N	C	N	CH ₃	CH ₃	-	OCH ₃	H	p-HOPh	H
132	N	C	N	CH ₃	CH ₃	-	OCH ₃	H	p-(CH ₃) ₂ NPh	H
133	N	C	N	CH ₃	CH ₃	-	OCH ₃	H	p-N ₃ Ph	H
134	N	C	N	CH ₃	CH ₃	-	OCH ₃	H	furan	H
135	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-BrPh	p-BrPh	H
136	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-CH ₃ Ph	p-CH ₃ Ph	H
137	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-CH ₃ OPh	p-CH ₃ OPh	H
138	N	C	N	CH ₃	CH ₃	-	OCH ₃	p-(CH ₃) ₂ NPh	p-(CH ₃) ₂ NPh	H
139	N	C	N	CH ₃	CH ₃	-	OCH ₃	o-ClPh	o-ClPh	H
140	N	C	N	CH ₃	CH ₃	-	OCH ₃	m-CH ₃ OPh	m-CH ₃ OPh	H
141	N	C	N	CH ₃	CH ₃	-	OCH ₃	3-Br-6-OHPh	3-Br-6-OHPh	H
142	N	C	N	CH ₃	CH ₃	-	OCH ₃	furan-2-yl	furan-2-yl	H
143	N	C	N	CH ₃	CH ₃	-	OCH ₃	thiophene-2-yl	thiophene-2-yl	H
144	N	C	N	CH ₃	CH ₃	-	OCH ₃	pyridine-2-yl	pyridine-2-yl	H
145	N	C	N	CH ₃	CH ₃	-	OCH ₃	6-CH ₃ pyridine-2-yl	6-CH ₃ pyridine-2-yl	H
146	N	C	N	CH ₃	CH ₃	-	H	p-CH ₃ Ph	H	H
147	N	C	N	CH ₃	CH ₃	-	H	p-CH ₃ OPh	H	H
148	N	C	N	CH ₃	CH ₃	-	H	p-HOPh	H	H
149	N	C	N	CH ₃	CH ₃	-	H	p-(CH ₃) ₂ NPh	H	H
150	N	C	N	CH ₃	CH ₃	-	H	p-N ₃ Ph	H	H
151	N	C	N	CH ₃	CH ₃	-	H	furan	H	H
152	N	C	N	CH ₃	CH ₃	-	H	H	p-NO ₂ Ph	H
153	N	C	N	CH ₃	CH ₃	-	H	H	p-CH ₃ Ph	H
154	N	C	N	CH ₃	CH ₃	-	H	H	p-CH ₃ OPh	H
155	N	C	N	CH ₃	CH ₃	-	H	H	p-HOPh	H
156	N	C	N	CH ₃	CH ₃	-	H	H	p-(CH ₃) ₂ NPh	H
157	N	C	N	CH ₃	CH ₃	-	H	H	p-N ₃ Ph	H
158	N	C	N	CH ₃	CH ₃	-	H	H	furan	H
159	N	C	N	CH ₃	CH ₃	-	H	p-BrPh	p-BrPh	H

Compound No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
160	N	C	N	CH ₃	CH ₃	-	H	p-CH ₃ Ph	p-CH ₃ Ph	H
161	N	C	N	CH ₃	CH ₃	-	H	p-CH ₃ OPh	p-CH ₃ OPh	H
162	N	C	N	CH ₃	CH ₃	-	H	p-(CH ₃) ₂ NPh	p-(CH ₃) ₂ NPh	H
163	N	C	N	CH ₃	CH ₃	-	H	o-ClPh	o-ClPh	H
164	N	C	N	CH ₃	CH ₃	-	H	m-CH ₃ OPh	m-CH ₃ OPh	H
165	N	C	N	CH ₃	CH ₃	-	H	3-Br-6-OHPh	3-Br-6-OHPh	H
166	N	C	N	CH ₃	CH ₃	-	H	furan-2-yl	furan-2-yl	H
167	N	C	N	CH ₃	CH ₃	-	H	thiophene-2-yl	thiophene-2-yl	H
168	N	C	N	CH ₃	CH ₃	-	H	pyridine-2-yl	pyridine-2-yl	H
169	N	C	N	CH ₃	CH ₃	-	H	6-CH ₃ pyridine-2-yl	6-CH ₃ pyridine-2-yl	H
170	N	C	N	CH ₃	CH ₃	-	H	Ph	H	H
171	N	C	N	CH ₃	CH ₃	-	H	H	Ph	H
172	N	C	N	CH ₃	CH ₃	-	H	Ph	Ph	H
173	N	C	N	CH ₃	CH ₃	-	H	CH ₃	H	H
174	N	C	N	CH ₃	CH ₃	-	H	H	CH ₃	H
175	N	C	N	CH ₃	CH ₃	-	H	CH ₃	CH ₃	H
176	N	C	N	CH ₃	CH ₃	-	CH ₃	p-CH ₃ Ph	H	H
177	N	C	N	CH ₃	CH ₃	-	CH ₃	p-CH ₃ OPh	H	H
178	N	C	N	CH ₃	CH ₃	-	CH ₃	p-HOPh	H	H
179	N	C	N	CH ₃	CH ₃	-	CH ₃	p-(CH ₃) ₂ NPh	H	H
180	N	C	N	CH ₃	CH ₃	-	CH ₃	p-N ₃ Ph	H	H
181	N	C	N	CH ₃	CH ₃	-	CH ₃	furan	H	H
182	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-NO ₂ Ph	H
183	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-CH ₃ Ph	H
184	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-CH ₃ OPh	H
185	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-HOPh	H
186	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-(CH ₃) ₂ NPh	H
187	N	C	N	CH ₃	CH ₃	-	CH ₃	H	p-N ₃ Ph	H
188	N	C	N	CH ₃	CH ₃	-	CH ₃	H	furan	H
189	N	C	N	CH ₃	CH ₃	-	CH ₃	p-BrPh	p-BrPh	H
190	N	C	N	CH ₃	CH ₃	-	CH ₃	p-CH ₃ Ph	p-CH ₃ Ph	H
191	N	C	N	CH ₃	CH ₃	-	CH ₃	p-CH ₃ OPh	p-CH ₃ OPh	H

Compound No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
192	N	C	N	CH ₃	CH ₃	-	CH ₃	p-(CH ₃) ₂ NPh	p-(CH ₃) ₂ NPh	H
193	N	C	N	CH ₃	CH ₃	-	CH ₃	o-ClPh	o-ClPh	H
194	N	C	N	CH ₃	CH ₃	-	CH ₃	m-CH ₃ OPh	m-CH ₃ OPh	H
195	N	C	N	CH ₃	CH ₃	-	CH ₃	3-Br-6-OHPh	3-Br-6-OHPh	H
196	N	C	N	CH ₃	CH ₃	-	CH ₃	furan-2-yl	furan-2-yl	H
197	N	C	N	CH ₃	CH ₃	-	CH ₃	thiophene-2-yl	thiophene-2-yl	H
198	N	C	N	CH ₃	CH ₃	-	CH ₃	pyridine-2-yl	pyridine-2-yl	H
199	N	C	N	CH ₃	CH ₃	-	CH ₃	6-CH ₃ pyridine-2-yl	6-CH ₃ pyridine-2-yl	H
200	N	C	N	CH ₃	CH ₃	-	CH ₃	Ph	H	H
201	N	C	N	CH ₃	CH ₃	-	CH ₃	H	Ph	H
202	N	C	N	CH ₃	CH ₃	-	CH ₃	Ph	Ph	H
203	N	C	N	CH ₃	CH ₃	-	CH ₃	CH ₃	CH ₃	H
204	N	C	N	CH ₃	CH ₃	-	H	H	p-NO ₂ Ph	H
205	N	C	N	CH ₃	CH ₃	-	H	H	p-CH ₃ Ph	H
206	N	C	N	CH ₃	CH ₃	-	H	H	p-CH ₃ OPh	H
207	N	C	N	CH ₃	CH ₃	-	H	H	p-HOPh	H
208	N	C	N	CH ₃	CH ₃	-	H	H	p-(CH ₃) ₂ NPh	H
209	N	C	N	CH ₃	CH ₃	-	H	H	p-N ₃ Ph	H
210	N	C	N	CH ₃	CH ₃	-	H	H	furan	H
211	N	C	N	CH ₃	CH ₃	-	H	p-BrPh	p-BrPh	H
212	N	C	N	CH ₃	CH ₃	-	H	p-CH ₃ Ph	p-CH ₃ Ph	H
213	N	C	N	CH ₃	CH ₃	-	H	p-CH ₃ OPh	p-CH ₃ OPh	H
214	N	C	N	CH ₃	CH ₃	-	H	p-(CH ₃) ₂ NPh	p-(CH ₃) ₂ NPh	H
215	N	C	N	CH ₃	CH ₃	-	H	o-ClPh	o-ClPh	H
216	N	C	N	CH ₃	CH ₃	-	H	m-CH ₃ OPh	m-CH ₃ OPh	H
217	N	C	N	CH ₃	CH ₃	-	H	3-Br-6-OHPh	3-Br-6-OHPh	H
218	N	C	N	CH ₃	CH ₃	-	H	furan-2-yl	furan-2-yl	H
219	N	C	N	CH ₃	CH ₃	-	H	thiophene-2-yl	thiophene-2-yl	H
220	N	C	N	CH ₃	CH ₃	-	H	pyridine-2-yl	pyridine-2-yl	H
221	N	C	N	CH ₃	CH ₃	-	H	6-CH ₃ pyridine-2-yl	6-CH ₃ pyridine-2-yl	H
222	N	C	N	CH ₃	CH ₃	-	H	Ph	H	H
223	N	C	N	CH ₃	CH ₃	-	H	H	Ph	H

Compound No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
224	N	C	N	CH ₃	CH ₃	-	H	Ph	Ph	H
225	N	C	N	CH ₃	CH ₃	-	H	CH ₃	H	H
226	N	C	N	CH ₃	CH ₃	-	H	H	CH ₃	H
227	N	C	N	CH ₃	CH ₃	-	H	CH ₃	CH ₃	H

2. THE BIOCHEMISTRY

In yet another embodiment, this invention relates to a method for the modulation of the catalytic activity of PTKs comprising administering a compound of this invention or a 5 physiologically acceptable salt or a prodrug thereof to a PTK.

By "PTK" is meant both RTKs and CTKs; i.e., the modulation of both RTK signal transduction and CTK signal transduction is contemplated by this invention.

The term "method" refers to manners, means, techniques and 10 procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical 15 arts.

As used herein, the term "modulation" or "modulating" refers to the alteration of the catalytic activity of RTKs and/or CTKs. In particular, modulating refers to the activation of the catalytic activity of RTKs and/or CTKs, more preferably 20 to the activation or inhibition of the catalytic activity of RTKs and/or CTKs, depending on the concentration of the compound administered or, more preferably still, to the inhibition of the catalytic activity of RTKs and/or CTKs.

The term "catalytic activity" as used herein refers to the 25 rate of phosphorylation of tyrosine under the influence, direct or indirect, of RTKs and/or CTKs.

The term "administering" as used herein refers to a method for bringing a compound of this invention and a target PK together in such a manner that the compound can affect the catalytic activity of the PK either directly; i.e., by 5 interacting with the kinase itself, or indirectly; i.e., by interacting with another molecule on which the catalytic activity of the kinase is dependent. As used herein, administration can be accomplished either in vitro, i.e. in a test tube, or in vivo, i.e. in cells or tissues of a living 10 organism. Thus, the PTK mediated disorders which are the object of this invention can be studied, prevented or treated by the methods set forth herein whether the cells or tissues of the organism exist within the organism or outside the organism.

Cells existing outside the organism can be maintained or grown 15 in cell culture dishes. In this context, the ability of a particular compound to affect a PTK related disorder can be determined; i.e., the IC50 of the compound, defined below, can be ascertained before the use of the compounds in more complex living organisms is attempted. For cells outside the organism, 20 multiple methods exist, and are well-known to those skilled in the art, to administer compounds including, but not limited to, direct cell microinjection and numerous transmembrane carrier techniques. For cells harbored within a living organism, myriad methods also exist, and are likewise well-known to those 25 skilled in the art, to administer compounds including, but not limited to, oral, parenteral, dermal and aerosol applications.

RTK mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response (e.g., cell division or metabolic responses to the extracellular microenvironment). See, Schlessinger and Ullrich, 1992, Neuron 9:303-391.

It has been shown that tyrosine phosphorylation sites in growth factor receptors function as high-affinity binding sites for SH2 (src homology) domains of signaling molecules. Fantl et al., 1992, Cell 69:413-423; Songyang et al., 1994, Mol. Cell. Biol. 14:2777-2785); Songyang et al., 1993, Cell 72:767-778; and Koch et al., 1991, Science 252:668-678. Several intracellular substrate proteins that associate with RTKs have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such domain but serve as adapters and associate with catalytically active molecules. Songyang et al., 1993, Cell 72:767-778. The specificity of the interactions between receptors and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences

in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles.

5 Songyang et al., 1993, Cell 72:767-778. These observations suggest that the function of each RTK is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation
10 provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

PTK signal transduction results in, among other responses, cell proliferation, differentiation, growth and metabolism.

15 Abnormal cell proliferation may result in a wide array of disorders and diseases, including the development of neoplasia such as carcinoma, sarcoma, leukemia, glioblastoma and hemangioma; psoriasis, arteriosclerosis, arthritis and diabetic retinopathy and other disorders related to uncontrolled
20 angiogenesis and/or vasculogenesis.

A precise understanding of the mechanism by which the compounds of this invention inhibit PTKs is not required in order to practice the present invention. However, while not being bound to any particular mechanism or theory, it is
25 believed that the compounds interact with the amino acids of the catalytic region of PTKs. PTKs typically possess a bi-

lobate structure wherein ATP appears to bind in the cleft between the two lobes in a region where the amino acids are conserved among PTKs. Inhibitors of PTKs are believed to bind by non-covalent interactions such as hydrogen bonding, van der Waals forces and ionic interactions in the same general region where the aforesaid ATP binds to the PTKs. More specifically, it is thought that the quinoxaline ring component of the compounds of this invention binds in the general space normally occupied by the adenine ring of ATP. Specificity of a particular quinoxaline for a particular PTK may arise as the result of additional interactions between the various substituents on the quinoxaline core and the amino acid domain specific to particular PTKs. That is, different quinoxaline substituents may contribute to preferential binding to particular PTKs. The ability to select compounds active at different ATP (or other nucleotide) binding sites makes the compounds of this invention useful for targeting any protein with such a site; i.e., not only PTKs but serine/threonine kinases and protein phosphatases as well. Thus, the compounds disclosed herein may be useful as in vitro assays for such proteins as well as in vivo therapeutic agents acting through such proteins.

Thus, in another aspect, this invention relates to a method for treating or preventing a PTK related disorder by administering a therapeutically effective amount of a compound of this invention or a salt or a prodrug thereof to an

organism.

In addition to the compounds described above, the compounds shown in Table 2, below, are expected to be useful in treating or preventing PTK related disorders in an organism.

























5 As used herein, "PTK related disorder," "PTK driven disorder," and "abnormal PTK activity" all refer to a disorder characterized by inappropriate PTK activity or over-activity of the PTK, which can be either an RTK or a CTK. Inappropriate activity refers to either: (1) PTK expression in cells which 10 normally do not express PTKs; (2) increased PTK expression leading to unwanted cell proliferation, differentiation and/or growth; or, (3) decreased PTK expression leading to unwanted reductions in cell proliferation, differentiation and/or growth. Overactivity of PTKs refers to either amplification of 15 the gene encoding a particular PTK or production of a level of PTK activity which can correlate with a cell proliferation, differentiation and/or growth disorder (that is, as the level of the PTK increases, the severity of one or more of the symptoms of the cellular disorder increases).

20 As used herein, the terms "prevent", "preventing" and "prevention" refer to a method for barring an organism from acquiring a PTK mediated cellular disorder in the first place.

TABLE 2

Compound	No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
	228	N	C	N	H	OH	-	H	Ph	Ph	H
	229	N	C	N	Cl	CF ₃	-	H	Cl	Cl	H
	230	N	C	N	H	CH ₃	-	H	Ph	Ph	H
	231	N	C	N	CH ₃	CH ₃	-	H	Ph	Ph	H
	232	N	C	N	CH ₃ C(=O)-	CH ₃	-	H	CH ₃	CH ₃	H
	233	N	C	N	CH ₃	CH ₃	-	H	H	H	H
	234	N	C	N	CH ₃	CH ₃	-	H	CH ₃	CH ₃	H
	235	N	C	N	CH ₃	NH ₂	-	H	H	CH ₃	CH ₃
	236	N	C	N	CH ₃	CH ₃	-	H	Ph	H	H
	237	N	C	N	CH ₃	CH ₃	-	H	H	Ph	H
	238	N	C	N	H	CH ₃	-	H	H	Ph	H
	239	N	C	N	CH ₃	CH ₃	-	H	H	CH ₃	CH ₃
	240	O	N	C	-	p-CH ₃ Ph-	-OCH ₃	p-CH ₃ Ph-	p-CH ₃ Ph-	-OCH ₃	H
	241	N	N	C	CH ₃	H	-OCH ₃	p-CH ₃ Ph-	p-CH ₃ Ph-	-OCH ₃	H
	242	N	C	C	H	H	H	H	Ph	Ph	H
	243	S	C	N	-	CH ₃	-	H	OH	CH ₃	H
	244	S	C	N	-	CH ₃	-	H	OH	OH	H
	245	S	C	N	-	H	-	H	CH ₃	CH ₃	H
	246	S	C	N	-	CH ₃	-	H	Ph	H	H
	247	S	C	N	-	CH ₃	-	H	H	Ph	H
	248	S	C	N	-	CH ₃	-	H	CH ₃	CH ₃	H
	249	S	C	N	-	CH ₃	-	H	Ph	Ph	H
	250	S	C	N	-	CH ₃	-	H	H	H	H

Compound

No.	A	B	D	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
251	S	C	N	-	CH ₃	-	H	CH ₃	OH	H
252	S	C	N	-	CH ₃ OC(=O)-	CH ₃	-OCH ₃	Et ₂ NCH ₂ Ph-	Et ₂ NCH ₂ Ph-	H
253	S	C	N	-	CH ₃ OC(=O)-	CH ₃	-OCH ₃	Me ₂ NCH ₂ Ph-	Me ₂ NCH ₂ Ph-	H
254	S	C	N	-	H ₂ NC(=O)-	CH ₃	-OCH ₃			H
255	S	C	N	-	CH ₃ OC(=O)-	CH ₃	-OCH ₃			H
256	S	C	N	-	HOC(-O)-	CH ₃	-OCH ₃			H
257	S	C	N	-		H ₃	-OCH ₃			H
258	S	C	N	-	CH ₃ OC(=O)-	H ₃	-OCH ₃			H
259	S	C	N	-	Et ₂ NC(=O)-	CH ₃	-OCH ₃			H
260	S	C	N	-	CH ₃ OC(=O)-	CH ₃	-OCH ₃	nPr ₂ NCH ₂ Ph-	nPr ₂ NCH ₂ Ph-	H
261	S	C	N	-	CH ₃ O(C=O)-	CH ₃	-OCH ₃			H
262	S	C	N	-	CH ₃ O(C=O)-	CH ₃	-OCH ₃			H
263	S	C	N	-	CH ₃ O(C=O)-	CH ₃	-OCH ₃			H
264	S	C	N	-		CH ₃	-OCH ₃			H
265	S	C	N	-	CH ₃ O(C=O)-	CH ₃	-OCH ₃			H
266	S	C	N	-	HO(C=O)-	CH ₃	-OCH ₃			H
267	S	C	N	-	CH ₃ OC(=O)-	CH ₃	-OCH ₃	p-CH ₃ Ph-	p-CH ₃ Ph-	H
268	S	C	N	-		CH ₃	-OCH ₃			H
269	S	C	N	-	CH ₃ O(C=O)-	CH ₃	-OCH ₃	p-BrCH ₂ Ph-	p-BrCH ₂ Ph-	H
270	N	C	C	CH ₃	H	H	H	H	H	H

As used herein, the terms "treat", "treating" and "treatment" refer to a method of alleviating or abrogating the PTK mediated cellular disorder and/or its attendant symptoms. With regard particularly to cancer, these terms simply mean 5 that the life expectancy of an individual affected with a cancer will be increased or that one or more of the symptoms of the disease will be reduced.

As used herein, the term "cancer" refers to various types of malignant neoplasms, most of which can invade surrounding 10 tissues, and may metastasize to different sites, as defined by Stedman's Medical Dictionary 25th edition (Hensyl ed. 1990). Examples of cancers which may be treated by the present invention include, but are not limited to, brain, ovarian, colon, prostate, kidney, bladder, breast, lung, oral and skin 15 cancers which exhibit inappropriate PTK activity. These cancers can be further broken down. For example, brain cancers include glioblastoma multiforme, anaplastic astrocytoma, astrocytoma, ependymoma, oligodendrogloma, medulloblastoma, meningioma, sarcoma, hemangioblastoma, and pineal parenchymal. 20 Likewise, skin cancers include melanoma and Kaposi's sarcoma.

The term "organism" refers to any living entity comprised of at least one cell. A living organism can be as simple as, for example, a single eukaryotic cell or as complex as a mammal, including a human being.

25 The term "therapeutically effective amount" as used herein refers to that amount of the compound being administered which

will relieve to some extent one or more of the symptoms of the disorder being treated. In reference to the treatment of cancer, a therapeutically effective amount refers to that amount which has the effect of (1) reducing the size of the tumor; (2) inhibiting (that is, slowing to some extent, preferably stopping) tumor metastasis; (3) inhibiting to some extent (that is, slowing to some extent, preferably stopping) tumor growth; and/or, (4) relieving to some extent (or preferably eliminating) one or more symptoms associated with the cancer.

This invention is therefore directed to compounds which modulate PTK signal transduction by affecting the enzymatic activity of the RTKs and/or CTKs and thereby interfering with the signal transduced by such proteins. More particularly, the present invention is directed to compounds which modulate the RTK and/or CTK mediated signal transduction pathways as a therapeutic approach to cure many kinds of solid tumors, including but not limited to carcinoma, sarcoma, erythroblastoma, glioblastoma, meningioma, astrocytoma, melanoma and myoblastoma. Indications may include, but are not limited to, brain cancers, bladder cancers, ovarian cancers, gastric cancers, pancreas cancers, colon cancers, blood cancers, lung cancers, bone cancers and leukemias.

Further examples, without limitation, of the types of disorders related to unregulated PTK activity that the compounds described herein may be useful in preventing,

treating and studying are cell proliferative disorders, fibrotic disorders and metabolic disorders.

Cell proliferative disorders which may be prevented, treated or further studied by the present invention include 5 cancer, blood vessel proliferative disorders and mesangial cell proliferative disorders.

Blood vessel proliferative disorders refer to angiogenic and vasculogenic disorders generally resulting in abnormal proliferation of blood vessels. The formation and spreading of 10 blood vessels, or vasculogenesis and angiogenesis, respectively, play important roles in a variety of physiological processes such as embryonic development, corpus luteum formation, wound healing and organ regeneration. They also play a pivotal role in cancer development. Other examples 15 of blood vessel proliferation disorders include arthritis, where new capillary blood vessels invade the joint and destroy cartilage, and ocular diseases, like diabetic retinopathy, where new capillaries in the retina invade the vitreous, bleed and cause blindness. Conversely, disorders related to the 20 shrinkage, contraction or closing of blood vessels, such as restenosis, are also implicated.

Fibrotic disorders refer to the abnormal formation of extracellular matrices. Examples of fibrotic disorders include hepatic cirrhosis and mesangial cell proliferative disorders. 25 Hepatic cirrhosis is characterized by the increase in extracellular matrix constituents resulting in the formation of

a hepatic scar. Hepatic cirrhosis can lead to diseases such as cirrhosis of the liver. An increased extracellular matrix resulting in a hepatic scar can also be caused by viral infection such as hepatitis. Lipocytes appear to play a major 5 role in hepatic cirrhosis. Other fibrotic disorders implicated include atherosclerosis.

Mesangial cell proliferative disorders refer to disorders brought about by abnormal proliferation of mesangial cells. Mesangial proliferative disorders include various human renal 10 diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies. In this regard, PDGFR has been implicated in the maintenance of mesangial cell proliferation. Floege et al., 1993, Kidney 15 International 43:47S-54S.

As noted previously, PTKs have been associated with the development of cancer. Some of these receptors, like EGFR (Tuzi et al., 1991, Br. J. Cancer 63:227-233; Torp et al., 1992, APMIS 100:713-719); HER2/neu (Slamon et al., 1989, 20 Science 244:707-712) and PDGFR (Kumabe et al., 1992, Oncogene, 7:627-633) are over-expressed in many tumors and/or are persistently activated by autocrine loops. In fact, in the most common and severe cancers, such receptor over-expression and autocrine loops have been demonstrated (Akbasak and Suner- 25 Akbasak et al., 1992, J. Neurol. Sci., 111:119-133; Dickson et al., 1992, Cancer Treatment Res. 61:249-273; Korc et al.,

1992, J. Clin. Invest. 90:1352-1360); (Lee and Donoghue, 1992, J. Cell. Biol., 118:1057-1070; Korc et al., supra; Akbasak and Suner-Akbasak et al., supra). For example, the EGFR receptor has been associated with squamous cell carcinoma, astrocytoma, 5 glioblastoma, head and neck cancer, lung cancer and bladder cancer. HER2 has been associated with breast, ovarian, gastric, lung, pancreas and bladder cancer. PDGFR has been associated with glioblastoma, melanoma and lung, ovarian, and prostate cancer. The RTK c-met has been generally associated 10 with hepatocarcinogenesis and thus hepatocellular carcinoma. Additionally, c-met has been linked to malignant tumor formation. More specifically, c-met has been associated with, among other cancers, colorectal, thyroid, pancreatic and 15 gastric carcinoma, leukemia and lymphoma. Additionally, over-expression of the c-met gene has been detected in patients with Hodgkins disease and Burkitts disease.

IGF-IR, in addition to being implicated in nutritional support and in type-II diabetes, has also been associated with several types of cancers. For example, IGF-I has been 20 implicated as an autocrine growth stimulator for several tumor types including human breast cancer carcinoma cells (Arteaga et al., 1989, J. Clin. Invest. 84:1418-1423) and small lung tumor cells (Macauley et al., 1990, Cancer Res., 50:2511-2517). In addition, IGF-I, while being integrally involved in the normal 25 growth and differentiation of the nervous system, appears to be an autocrine stimulator of human gliomas. Sandberg-Nordqvist

et al., 1993, Cancer Res. 53:2475-2478. The importance of the IGF-IR and its ligands in cell proliferation is further supported by the fact that many cell types in culture (fibroblasts, epithelial cells, smooth muscle cells, T-lymphocytes, myeloid cells, chondrocytes and osteoblasts (the stem cells of the bone marrow)) are stimulated to grow by IGF-

5 I. Goldring and Goldring, 1991, Eukaryotic Gene Expression, 1:301-326. In a series of recent publications, Baserga even suggests that IGF-IR plays a central role in the 10 mechanisms of transformation and, as such, could be a preferred target for therapeutic interventions for a broad spectrum of human malignancies. Baserga, 1995, Cancer Res., 55:249-252; Baserga, 1994, Cell 79:927-930; Coppola et al., 1994, Mol. Cell. Biol., 14:4588-4595.

15 The association between abnormal RTK activity and disease are not restricted to cancer. For example, RTKs have been associated with metabolic diseases like psoriasis, diabetes mellitus, wound healing, inflammation, and neurodegenerative diseases. For example, EGFR has been indicated in corneal and 20 dermal wound healing. Defects in the Insulin-R and IGF-1R are indicated in type-II diabetes mellitus. A more complete correlation between specific RTKs and their therapeutic indications is set forth in Plowman et al., 1994, DN&P 7:334-339.

25 As noted previously, not only RTKs but CTks as well including, but not limited to, src, abl, fps, yes, fyn, lyn,

lck, blk, hck, fgr and yrk (reviewed by Bolen et al., 1992, FASEB J., 6:3403-3409) are involved in the proliferative and metabolic signal transduction pathway and thus were expected, and have been shown, to be involved in many PTK-mediated 5 disorders to which the present invention is directed. For example, mutated src (v-src) has been demonstrated as an oncoprotein (pp60^{v-src}) in chicken. Moreover, its cellular homolog, the proto-oncogene pp60^{c-src} transmits oncogenic signals of many receptors. Over-expression of EGFR or HER2/neu in 10 tumors leads to the constitutive activation of pp60^{c-src}, which is characteristic for the malignant cell but absent from the normal cell. On the other hand, mice deficient in the expression of c-src exhibit an osteopetrotic phenotype, indicating a key participation of c-src in osteoclast function 15 and a possible involvement in related disorders.

Similarly, Zap70 is implicated in T-cell signaling.

Finally, both RTKs and CTKs are currently suspected as being involved in hyperimmune disorders.

20 3. PHARMACOLOGICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS

A compound of the present invention, or its physiologically acceptable salt or prodrug, can be administered to a human patient per se, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s).

25 Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing

Co., Easton, PA, latest edition.

A. Routes Of Administration.

Suitable routes of administration may, for example, include oral, rectal, transmucosal, intestinal or parenteral 5 delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

Alternately, one may administer the compound in a local 10 rather than systemic manner, for example, via injection of the compound directly into a solid tumor, often in a depot or sustained release formulation.

Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a 15 tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

B. Composition/Formulation.

Another aspect of this invention relates to pharmaceutical compositions of the compounds described herein 20 and the physiologically acceptable salts and prodrugs thereof.

Pharmacological compositions of the present invention may be manufactured by processes well known in the art; e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or 25 lyophilizing processes.

Pharmacological compositions for use in accordance with

the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can 5 be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, 10 or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated 15 readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a 20 patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as 25 sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch,

wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If 5 desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which 10 may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee 15 coatings for identification or to characterize different combinations of active compound doses.

Pharmacological compositions which can be used orally include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the 20 active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid 25 polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages

suitable for the chosen route of administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use 5 according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a 10 pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

15 The compounds described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers with, optionally, an added preservative. The 20 compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmacological compositions for parenteral administration include aqueous solutions of the active compounds in water 25 soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection

suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances which increase the 5 viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

10 Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.

The compounds of this invention may also be formulated in rectal compositions such as suppositories or retention enemas, 15 using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, a compound of this invention may also be formulated as a depot preparation. Such long acting formulations may be administered 20 by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble 25 derivatives such as sparingly soluble salts.

The pharmacological compositions herein also may comprise

suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin and polymers such as
5 polyethylene glycols.

Many of the PTK modulating compounds of the invention may be provided as physiologically acceptable salts wherein the claimed compound may form the negatively or the positively charged species. Examples of salts in which the compound forms
10 the positively charged moiety include, without limitation, quaternary ammonium (defined elsewhere herein), salts such as the hydrochloride, sulfate, carbonate, lactate, tartrate, maleate, succinate, etc. wherein the nitrogen of the quaternary ammonium group is a nitrogen of a compound of this invention
15 which reacts with an appropriate acid. Salts in which the compound forms the negatively charged species include, without limitation, the sodium, potassium, calcium and magnesium salts formed by the reaction of a carboxylic acid group in the molecule with the appropriate base (e.g. sodium hydroxide
20 (NaOH), potassium hydroxide (KOH), Calcium hydroxide (Ca(OH)₂), etc.).

C. Dosage.

Pharmacological compositions suitable for use in the present invention include compositions wherein the active
25 ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically

effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is 5 well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

For any compound used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from cell culture assays. For example, a dose can be 10 formulated in animal models to achieve a circulating concentration range that includes the IC_{50} as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the PTK activity). Such information can be used to more accurately determine useful 15 doses in humans.

Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the IC_{50} and the LD_{50} (both of which are discussed 20 further, infra) for a subject compound. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of 25 administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g.,

Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the kinase modulating effects, termed the minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data; e.g., the concentration necessary to achieve 50-90% inhibition of a kinase may be ascertained using the assays described herein.

10 Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. HPLC assays or bioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using the MEC value. Compounds should be administered using a regimen which 15 maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.

It is noted that, in the case of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration. In such cases, 20 other procedures known in the art can be employed to determine the effective local concentration.

The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment 25 of the prescribing physician, etc.

D. Packaging.

Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms 5 containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed 10 by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of the labeling approved by the U.S. Food and Drug Administration 15 for prescription drugs or of an approved product insert.

Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Suitable conditions indicated on 20 the label may include treatment of a tumor, inhibition of angiogenesis, treatment of fibrosis, diabetes, and the like.

4. BRIEF DESCRIPTION OF THE TABLES.

Table 1 shows the chemical structure of specific compounds 25 of this invention. The compounds shown are not to be construed as limiting the scope of this invention in any manner

whatsoever.

Table 2 shows the chemical structures of compounds which are not claimed herein as composition of matter but, rather, are claimed for their expected utility as modulators of PTK 5 activity and for the treatment and prevention of PTK-related disorders.

Table 3 shows the results of biological assays of some compounds of this invention. These results are provided as examples only and are not to be construed as limiting the scope 10 of this invention in any manner including compound structure, the PTK against which the demonstrative compounds show activity or the level of activity (IC50) shown. PDGFR, FLK-1R and EGFR Kinase are defined and discussed elsewhere herein. IC50 refers to that amount of the tested compound needed to effect a 50% 15 change in the activity of the PTK in comparison with a control in which no compound of this invention is present. With regard to the tests in the table, the 50% change being evaluated is a 50% inhibition of PTK activity compared to that in a control.

20 5. SYNTHESIS

The compounds of this invention may be readily synthesized using techniques well known in the chemical arts. Other synthetic pathways for forming the compounds of the invention will be apparent to those skilled in the art and are deemed to 25 be within the scope and spirit of this invention.

A. Examples.

The following are examples of the synthesis of specific tricyclic quinoxaline compounds of this invention. These syntheses are provided by way of example only are not to be
5 construed as limiting in any manner.

Example 1. **1,2-Dimethyl-6,7-bis(4-bromo-phenyl)imidazo[4,5-g]quinoxaline** (ref: *J. Gen. Chem. USSR (Engl. Transl.)*, EN, 1962, 32, 2829-2838) .

Step 1: **2-methyl-5,6-dinitrobenzimidazole**: To a solution
10 of 2-methyl-5-nitrobenzimidazole in concentrated sulfuric acid
was added fuming nitric acid at -5°C. Upon addition of the
fuming nitric acid, the reaction mixture was warmed to 0°C held
for 1h and poured into crushed ice. The precipitate which
formed was filtered, washed with water, and dried overnight at
15 40°C to give the title compound.

Step 2: **1,2-Dimethyl-5,6-dinitrobenzimidazole**: To a
solution of 2-methyl-5,6-dinitro-benzimidazole in 5% NaOH was
added methanol and dimethyl sulfate. The reaction mixture was
heated for 30 min at 90-95°C and then cooled to room
20 temperature. The precipitate which formed was filtered, washed
with 10% NaOH and then water, and dried overnight at 40°C to
yield 1,2-dimethyl-5,6-dinitrobenzimidazole.

Step 3: **1,2-Dimethyl-5,6-diaminobenzimidazole**: 1,2-Dimethyl-5,6- dinitrobenzimidazole was reduced with tin in
25 hydrochloric acid. The solution obtained from the reduction was

diluted with water, cooled to 10°C, and treated with 40% NaOH. The precipitate which formed was filtered, washed with water and recrystallized from alcohol to yield 1,2 dimethyl-5,6 diaminobenzimidazole.

5 Step 4: 1,2-Dimethyl-6,7-bis(4-bromophenyl)imidazo[4,5-g]quinoxaline: To a solution of 1,2-dimethyl-5,6-diaminobenzimidazole in methanol was added 4,4'-dibromo-benzil. The reaction mixture was refluxed for 3h and cooled to room temperature. The precipitate which formed was filtered 10 and recrystallized from n-butyl alcohol to give the title quinoxaline.

Example 2. 1,2,9-Trimethyl-6,7-bis(4-bromophenyl)-imidazol[4,5-g]quinoxaline (ref: Chem. Pharm. Bull. 1994, 42(2), 408-409.

15 3-Fluoro-2-methylaniline was acetylated with acetic acid anhydride to give 3-fluoro-2-methyl-N-acetylaniline. Displacing fluorine of the 3-fluoro-2-methyl-N-acetylaniline with methylamine followed by nitration, deacetylation and reduction of the nitro group with palladium or charcoal gave 20 1,2-diamino-3-methyl-4-methylaminobenzene. Condensation of 4,4'-dibromo-benzil with the 1,2-diamino-3-methyl-4-methylaminobenzene in refluxing methanol gave 2,3-bis(4-bromophenyl)-5-methyl-6-methylaminoquinoxaline which upon acetylation with acetic acid anhydride, nitration, reduction with palladium on charcoal and 25

cyclization gave the title compound.

Example 3. 2-Amino-6,7-bis(4-bromophenyl)-1,9-dimethyl-imidazol[4,5-g]quinoxaline

2,3-bis(4-bromophenyl)-5-methyl-6-methylaminoquinoxaline was 5 treated with trifluoroacetic anhydride to give 2,3-bis-(4-bromo phenyl)-5-methyl-6-(N-methyl-N-trifluoroacetyl amino)quinoxaline which was then nitrated with fuming nitric acid in trifluoroacetic anhydride followed by reduction with palladium on charcoal deprotection with potassium carbonate in methanol, and cyclization 10 with cyanogen bromide to yield the title compound.

Example 4. 6,7-Bis(4-bromophenyl)-2-Methylamino-1,9-dimethylimidazol-[4,5-g]quinoxaline

Methylation of 2-amino-6,7-bis(4-bromophenyl)-1,9-dimethyl- 15 imidazol[4,5-g]quinoxaline with methyl iodide in acetone in the presence of potassium carbonate gave the title compound.

6. BIOLOGICAL EVALUATION

It will be appreciated that, in any given series of 20 compounds, a spectrum of biological activity will be afforded.

In its most preferred embodiments, this invention relates to tricyclic quinoxaline compounds demonstrating the ability to modulate RTK and CTK activity. The following assays are employed to select those compounds demonstrating the optimal 25 degree of the desired activity.

As used herein, the phrase "optimal degree of the desired

activity" refers to the lowest IC50, defined elsewhere herein, against a PTK related to a particular disorder so as to provide an organism, preferably a human, with a therapeutically effective amount of a compound of this invention at the lowest 5 possible dosage.

B. Assay Procedures.

The following in vitro assays may be used to determine the level of activity and the effect of that activity produced by the compounds of the present invention with respect 10 to specific PTKs. Similar assays can be designed along the same lines for any PK using techniques well known in the art.

The cellular/catalytic assays described herein are performed in an ELISA format. The general procedure is as follows: a compound is introduced to cells expressing the test 15 kinase, either naturally or recombinantly, for a selected period of time after which, if the test kinase is a receptor, a ligand known to activate the receptor's activity is added. The cells are lysed and the lysate is transferred to the wells of an ELISA plate previously coated with a specific antibody 20 recognizing the substrate of the enzymatic phosphorylation reaction. Non-substrate components of the cell lysate are washed away and the amount of phosphorylation on the substrate is detected with an antibody specifically recognizing phosphotyrosine and is compared with that of control cells that 25 were not contacted with the test compound.

The cellular/biologic assays described herein measure the

amount of DNA made in response to activation of a test kinase, which is a general measure of a proliferative response. The general procedure for this assay is as follows: a compound is introduced to cells expressing the test kinase, either 5 naturally or recombinantly, for a selected period of time after which, if the test kinase is a receptor, a ligand known to activate the receptor's activity is added. After incubation at least overnight, a DNA labeling reagent such as Bromodeoxyuridine (BrdU) or 3H-thymidine is added. The amount 10 of labeled DNA is detected with either an anti-BrdU antibody or by measuring radioactivity and is compared to control cells not contacted with a test compound.

1. Cellular/Catalytic Assays

Enzyme linked immunosorbent assays (ELISA) may be used 15 to detect and measure the presence of PTK activity. The ELISA may be conducted according to known protocols which are described in, for example, Voller, et al., 1980, "Enzyme-Linked Immunosorbent Assay," In: Manual of Clinical Immunology, 2d ed., edited by Rose and Friedman, pp 359-371 Am. Soc. Of 20 Microbiology, Washington, D.C.

The disclosed protocol may be adapted for determining activity with respect to a specific PK. The preferred protocols for conducting the ELISA experiments for specific RTKs is provided below. Adaptation of these protocols for 25 determining a compound's activity for other members of the RTK family, as well as for CTks, is well within the scope of

knowledge of those skilled in the art.

a. FLK-1

An ELISA assay is conducted to measure the kinase activity of the FLK-1 receptor and more specifically, the inhibition or activation of TK activity on the FLK-1 receptor. Specifically, the following assay can be conducted to measure kinase activity of the FLK-1 receptor in cells genetically engineered to express Flk-1.

Materials And Methods.

10 **Materials.** The following reagents and supplies are used:

- a. Corning 96-well ELISA plates (Corning Catalog No. 25805-96);
- 15 b. Cappel goat anti-rabbit IgG (catalog no. 55641);
- c. PBS (Gibco Catalog No. 450-1300EB);
- 20 d. TBSW Buffer (50 mM Tris (pH 7.2), 150 mM NaCl and 0.1% Tween-20);
- e. Ethanolamine stock (10% ethanolamine (pH 7.0), stored at 4°C);
- 25 f. HNTG buffer (20mM HEPES buffer (pH 7.5), 150mM NaCl, 0.2% Triton X-100, and 10% glycerol);
- g. EDTA (0.5 M (pH 7.0) as a 100X stock);
- 30 h. Sodium orthovanadate (0.5 M as a 100X stock);
- i. Sodium pyrophosphate (0.2 M as a 100X stock);
- 35 j. NUNC 96 well V bottom polypropylene plates (Applied Scientific Catalog No. AS-72092);
- k. NIH3T3 C7#3 Cells (FLK-1 expressing cells);
- 40 l. DMEM with 1X high glucose L-Glutamine (catalog No. 11965-050);

- m. FBS, Gibco (catalog no. 16000-028);
- n. L-glutamine, Gibco (catalog no. 25030-016);
- 5 o. VEGF, PeproTech, Inc. (catalog no. 100-20) (kept as 1 μ g/100 μ l stock in Milli-Q dH₂O and stored at -20°C);
- 10 p. Affinity purified anti-FLK-1 antiserum;
- q. UB40 monoclonal antibody specific for phosphotyrosine (see, Fendley, et al., 1990, *Cancer Research* 50:1550-1558);
- 15 r. EIA grade Goat anti-mouse IgG-POD (BioRad catalog no. 172-1011);
- s. 2,2-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid (ABTS) solution (100mM citric acid (anhydrous), 250 mM Na₂HPO₄ (pH 4.0), 0.5 mg/ml ABTS (Sigma catalog no. A-1888)), solution should be stored in dark at 4°C until ready for use;
- 20 t. H₂O₂ (30% solution) (Fisher catalog no. H325);
- u. ABTS/H₂O₂ (15ml ABTS solution, 2 μ l H₂O₂) prepared 5 minutes before use and left at room temperature;
- 30 v. 0.2 M HCl stock in H₂O;
- w. dimethylsulfoxide (100%) (Sigma Catalog No. D-8418); and
- 35 y. Trypsin-EDTA (Gibco BRL Catalog No. 25200-049).

Protocol. The following protocol can be used for conducting the assay:

1. Coat Corning 96-well ELISA plates with 1.0 μ g per well Cappel Anti-rabbit IgG antibody in 0.1M Na₂CO₃, pH 9.6.

40 Bring final volume to 150 μ l per well. Coat plates overnight at 4°C. Plates can be kept up to two weeks when stored at 4°C.

2. Grow cells in Growth media(DMEM, supplemented with 2.0mM L-Glutamine, 10% FBS) in suitable culture dishes until confluent at 37°C, 5% CO₂.

3. Harvest cells by trypsinization and seed in Corning 5 25850 polystyrene 96-well round bottom cell plates, 25.000 cells/well in 200μl of growth media.

4. Grow cells at least one day at 37°C, 5% CO₂.

5. Wash cells with D-PBS 1X.

6. Add 200μl/well of starvation media (DMEM, 2.0mM 10 Glutamine, 0.1% FBS). Incubate overnight at 37°C, 5% CO₂.

7. Dilute Compounds 1:20 in polypropylene 96 well plates using starvation media. Dilute dimethylsulfoxide 1:20 for use in control wells.

8. Remove starvation media from 96 well cell culture 15 plates and add 162 μl of fresh starvation media to each well.

9. Add 18μl of 1:20 diluted Compound dilution (from step 7) to each well plus the 1:20 dimethylsulfoxide dilution to the control wells (+/- VEGF), for a final dilution of 1:200 after cell stimulation. Final dimethylsulfoxide is 0.5%.

20 Incubate the plate at 37°C, 5% CO₂ for two hours.

10. Remove unbound antibody from ELISA plates by inverting plate to remove liquid. Wash 3 times with TBSW + 0.5% ethanolamine, pH 7.0. Pat the plate on a paper towel to remove excess liquid and bubbles.

25 11. Block plates with TBSW + 0.5% Ethanolamine, pH 7.0,

150 μ l per well. Incubate plate thirty minutes while shaking on a microtiter plate shaker.

12. Wash plate 3 times as described in step 10.

13. Add 0.5 μ g/well affinity purified anti-FLU-1 5 polyclonal rabbit antiserum. Bring final volume to 150 μ l/well with TBSW + 0.5% ethanolamine pH 7.0. Incubate plate for thirty minutes while shaking.

14. Add 180 μ l starvation medium to the cells and stimulate cells with 20 μ l/well 10.0mM sodium ortho vanadate and 10 500 ng/ml VEGF (resulting in a final concentration of 1.0mM sodium ortho vanadate and 50ng/ml VEGF per well) for eight minutes at 37°C, 5% CO₂. Negative control wells receive only starvation medium.

15. After eight minutes, media should be removed from 15 the cells and washed one time with 200 μ l/well PBS.

16. Lyse cells in 150 μ l/well HNTG while shaking at room temperature for five minutes. HNTG formulation includes sodium ortho vanadate, sodium pyrophosphate and EDTA.

17. Wash ELISA plate three times as described in step 10.

20 18. Transfer cell lysates from the cell plate to ELISA plate and incubate while shaking for two hours. To transfer cell lysate pipette up and down while scrapping the wells.

19. Wash plate three times as described in step 10.

20. Incubate ELISA plate with 0.02 μ g/well UB40 in TBSW 25 + 05% ethanolamine. Bring final volume to 150 μ l/well.

Incubate while shaking for 30 minutes.

21. Wash plate three times as described in step 10.

22. Incubate ELISA plate with 1:10,000 diluted EIA grade goat anti-mouse IgG conjugated horseradish peroxidase in 5 TBSW + 0.5% ethanolamine, pH 7.0. Bring final volume to 150 μ l/well. Incubate while shaking for thirty minutes.

23. Wash plate as described in step 10.

24. Add 100 μ l of ABTS/H₂O₂ solution to well. Incubate ten minutes while shaking.

10 25. Add 100 μ l of 0.2 M HCl for 0.1 M HCl final to stop the color development reaction. Shake 1 minute at room temperature. Remove bubbles with slow stream of air and read the ELISA plate in an ELISA plate reader at 410 nm.

15 b. HER-2 ELISA

Assay 1: EGF Receptor-HER2 Chimeric Receptor Assay In Whole Cells.

HER2 kinase activity in whole EGFR-NIH3T3 cells are measured as described below:

20 Materials and Reagents. The following materials and reagents can be used to conduct the assay:

a. EGF: stock concentration: 16.5 ILM; EGF 201, TOYOB_O, Co., Ltd. Japan.

25 b. 05-101 (UBI) (a monoclonal antibody recognizing an EGFR extracellular domain).

c. Anti-phosphotyrosine antibody (anti-Ptyr) (polyclonal) (see, Fendley, et al., *supra*).

d. Detection antibody: Goat anti-rabbit IgG horse radish peroxidase conjugate, TAGO, Inc., Burlingame, CA.

5

e. TBST buffer:

Tris-HCl, pH 7.2 50 mM
NaCl 150 mM
Triton X-100 0.1

10

f. HNTG 5x stock:

HEPES	0.1 M
NaCl	0.75 M
Glycerol	50%
Triton X-100	1.0%

15

q. ABTS stock:

20

Citric Acid	100 mM
Na ₂ HPO ₄	250 mM
HCl, conc.	0.5 pM
ABTS*	0.5mg/ml

25

* (2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid)). Keep solution in dark at 4°C until use.

h. Stock reagents of:

30

EDTA 100 mM pH 7.0
 Na_3VO_4 0.5 M
 $\text{Na}_4(\text{P}_2\text{O}_7)$ 0.2 M

Procedure. The following protocol is used:

A. Pre-coat ELISA Plate

35

1. Coat ELISA plates (Corning, 96 well, Cat.

#25805-96) with 05-101 antibody at 0.5 g per well in PBS, 100 μ l final volume/well, and store overnight at 4°C. Coated plates are good for up to 10 days when stored at 4°C.

2. On day of use, remove coating buffer and
40 replace with 100 µl blocking buffer (5% Carnation Instant Non-
Fat Dry Milk in PBS). Incubate the plate, shaking, at room

temperature (about 23°C to 25°C) for 30 minutes. Just prior to use, remove blocking buffer and wash plate 4 times with TBST buffer.

B. Seeding Cells

5 1. An NIH3T3 cell line overexpressing a chimeric receptor containing the EGFR extracellular domain and intracellular HER2 kinase domain can be used for this assay.

10 2. Choose dishes having 80-90% confluence for the experiment. Trypsinize cells and stop reaction by adding 10% fetal bovine serum. Suspend cells in DMEM medium (10% CS DMEM medium) and centrifuge once at 1500 rpm, at room temperature for 5 minutes.

15 3. Resuspend cells in seeding medium (DMEM, 0.5% bovine serum), and count the cells using trypan blue. Viability above 90% is acceptable. Seed cells in DMEM medium (0.5% bovine serum) at a density of 10,000 cells per well, 100 µl per well, in a 96 well microtiter plate. Incubate seeded cells in 5% CO₂ at 37°C for about 40 hours.

C. Assay Procedures

20 1. Check seeded cells for contamination using an inverted microscope. Dilute drug stock (10 mg/ml in DMSO) 1:10 in DMEM medium, then transfer 5 µl to a TBST well for a final drug dilution of 1:200 and a final DMSO concentration of 1%. Control wells receive DMSO alone. Incubate in 5% CO₂ at 37°C for two hours.

2. Prepare EGF ligand: dilute stock EGF in DMEM so that upon transfer of 10 μ l dilute EGF (1:12 dilution), 100 nM final concentration is attained.

3. Prepare fresh HNTG* sufficient for 100 μ l per 5 well; and place on ice.

HNTG* (10 ml):

HNTG stock	2.0 ml
milli-Q H ₂ O	7.3 ml
EDTA, 100 mM, pH 7.0	0.5 ml
10 Na ₃ VO ₄ , 0.5 M	0.1 ml
Na ₄ (P ₂ O ₇), 0.2 M	0.1 ml

4. After 120 minutes incubation with drug, add prepared SGF ligand to cells, 10 μ l per well, to a final concentration of 100 nM. Control wells receive DMEM alone.

15 Incubate, shaking, at room temperature, for 5 minutes.

5. Remove drug, EGF, and DMEM. Wash cells twice with PBS. Transfer HNTG* to cells, 100 μ l per well. Place on ice for 5 minutes. Meanwhile, remove blocking buffer from other ELISA plate and wash with TBST as described above.

20 6. With a pipette tip securely fitted to a micropipettor, scrape cells from plate and homogenize cell material by repeatedly aspirating and dispensing the HNTG* lysis buffer. Transfer lysate to a coated, blocked, and washed ELISA plate. Incubate shaking at room temperature for one hour.

25 7. Remove lysate and wash 4 times with TBST.

Transfer freshly diluted anti-Ptyr antibody to ELISA plate at 100 μ l per well. Incubate shaking at room temperature for 30 minutes in the presence of the anti-Ptyr antiserum (1:3000 dilution in TBST).

5 8. Remove the anti-Ptyr antibody and wash 4 times with TBST. Transfer the freshly diluted TAGO anti-rabbit IgG antibody to the ELISA plate at 100 μ l per well. Incubate shaking at room temperature for 30 minutes (anti-rabbit IgG antibody: 1:3000 dilution in TBST).

10 9. Remove TAGO detection antibody and wash 4 times with TBST. Transfer freshly prepared ABTS/H₂O₂ solution to ELISA plate, 100 μ l per well. Incubate shaking at room temperature for 20 minutes. (ABTS/H₂O₂ solution: 1.0 μ l 30% H₂O₂ in 10 ml ABTS stock).

15 10. Stop reaction by adding 50 μ l 5N H₂SO₄ (optional), and determine O.D. at 410 nm.

11. The maximal phosphotyrosine signal is determined by subtracting the value of the negative controls from the positive controls. The percent inhibition of 20 phosphotyrosine content for extract-containing wells is then calculated, after subtraction of the negative controls.

c. PDGF-R ELISA

All cell culture media, glutamine, and fetal bovine serum can be purchased from Gibco Life 25 Technologies (Grand Island, NY) unless otherwise specified.

All cells are grown in a humid atmosphere of 90-95% air and 5-10% CO₂ at 37°C. All cell lines are routinely subcultured twice a week and are negative for mycoplasma as determined by the Mycotect method (Gibco).

5 For ELISA assays, cells (U1242, obtained from Joseph Schlessinger, NYU) are grown to 80-90% confluence in growth medium (MEM with 10% FBS, NEAA, 1 mM NaPyr and 2 mM GLN) and seeded in 96-well tissue culture plates in 0.5% serum at 25,000 to 30,000 cells per well. After overnight incubation in 0.5%
10 serum-containing medium, cells are changed to serum-free medium and treated with test compound for 2 hr in a 5% CO₂, 37°C incubator. Cells are then stimulated with ligand for 5-10 minute followed by lysis with HNTG (20 mM Hepes, 150 mM NaCl, 10% glycerol, 5 mM EDTA, 5 mM Na₂VO₄, 0.2% Triton X-100, and 2 mM NaPyr). Cell lysates (0.5 mg/well in PBS) are transferred
15 to ELISA plates previously coated with receptor-specific antibody and which had been blocked with 5% milk in TBST (50 mM Tris-HCl pH 7.2, 150 mM NaCl and 0.1% Triton X-100) at room temperature for 30 min. Lysates are incubated with shaking for
20 1 hour at room temperature. The plates are washed with TBST four times and then incubated with polyclonal anti-phosphotyrosine antibody at room temperature for 30 minutes. Excess anti-phosphotyrosine antibody is removed by rinsing the plate with TBST four times. Goat anti-rabbit IgG antibody is
25 added to the ELISA plate for 30 min at room temperature followed by rinsing with TBST four more times. ABTS (100 mM

citric acid, 250 mM Na₂HPO₄ and 0.5 mg/mL 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)) plus H₂O₂ (1.2 mL 30% H₂O₂ to 10 ml ABTS) is added to the ELISA plates to start color development. Absorbance at 410 nm with a reference wavelength 5 of 630 nm is recorded about 15 to 30 min after ABTS addition.

d. IGF-I RECEPTOR ELISA

The following protocol may be used to measure phosphotyrosine level on IGF-I receptor, which indicates IGF-I receptor tyrosine kinase activity.

10 **Materials And Reagents.** The following materials and reagents are used:

a. The cell line used in this assay is 3T3/IGF-1R, a cell line genetically engineered to overexpresses IGF-1 receptor.

15 b. NIH3T3/IGF-1R is grown in an incubator with 5% CO₂ at 37°C. The growth media is DMEM + 10% FBS (heat inactivated) + 2mM L-glutamine.

20 c. Affinity purified anti-IGF-1R antibody 17-69.

d. D-PBS:

25 KH₂PO₄ 0.20 g/l
 K₂HPO₄ 2.16 g/l
 KCl 0.20 g/l
 NaCl 8.00 g/l (pH 7.2)

30 e. Blocking Buffer: TBST plus 5% Milk (Carnation Instant Non-Fat Dry Milk).

f. TBST buffer:

35 Tris-HCl 50 mM
 NaCl 150mM (pH 7.2/HCl 10N)
 Triton X-100 0.1%

40 Stock solution of TBS (10X) is prepared, and Triton X-100 is added to the buffer during dilution.

g. HNTG buffer:

5 HEPES 20 mM
NaCl 150 mM (pH 7.2/HCl 1N)
Glycerol 10%
Triton X-100 0.2%

10 Stock solution (5X) is prepared and kept at 4°C.

15 h. EDTA/HCl: 0.5 M pH 7.0 (NaOH) as 100X stock.

20 i. Na₃VO₄: 0.5 M as 100X stock and aliquots are kept in -80°C.

25 j. Na₄P₂O₇: 0.2 M as 100X stock.

30 k. Insulin-like growth factor-1 from Promega (Cat# G5111).

35 l. Rabbit polyclonal anti-phosphotyrosine antiserum.

40 m. Goat anti-rabbit IgG, POD conjugate (detection antibody), Tago (Cat. No. 4520, Lot No. 1802): Tago, Inc., Burlingame, CA.

45 n. ABTS (2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid)) solution:

50 Citric acid 100 mM
Na₂HPO₄ 250 mM (pH 4.0/1 N HCl)
ABTS 0.5 mg/ml

55 ABTS solution should be kept in dark and 4°C. The solution should be discarded when it turns green.

60 o. Hydrogen Peroxide: 30% solution is kept in the dark and at 4°C.

65 **Procedure.** All the following steps are conducted at room temperature unless it is specifically indicated. All ELISA plate washings are performed by rinsing the plate with tap water three times, followed by one TBST rinse. Pat plate dry with paper towels.

A. Cell Seeding:

1. The cells, grown in tissue culture dish (Corning 25020-100) to 80-90% confluence, are harvested with Trypsin-EDTA (0.25%, 0.5 ml/D-100, GIBCO).

5 2. Resuspend the cells in fresh DMEM + 10% FBS + 2mM L-Glutamine, and transfer to 96-well tissue culture plate (Corning, 25806-96) at 20,000 cells/well (100 μ l/well). Incubate for 1 day then replace medium to serum-free medium (90/ μ l) and incubate in 5% CO₂ and 37°C overnight.

10

B. ELISA Plate Coating and Blocking:

1. Coat the ELISA plate (Corning 25805-96) with Anti-IGF-1R Antibody at 0.5 μ g/well in 100 μ l PBS at least 2 hours.

15 2. Remove the coating solution, and replace with 100 μ l Blocking Buffer, and shake for 30 minutes. Remove the blocking buffer and wash the plate just before adding lysate.

C. Assay Procedures:

20 1. The drugs are tested in serum-free condition.

2. Dilute drug stock (in 100% DMSO) 1:10 with DMEM in 96-well poly-propylene plate, and transfer 10 μ l/well of this solution to the cells to achieve final drug dilution 1:100, and final DMSO concentration of 1.0%. Incubate the 25 cells in 5% CO₂ at 37°C for 2 hours.

3. Prepare fresh cell lysis buffer (HNTG*)

	HNTG	2 ml
	EDTA	0.1 ml
	Na ₃ VO ₄	0.1 ml
5	Na ₄ (P ₂ O ₇)	0.1 ml
	H ₂ O	7.3 ml

4. After drug incubation for two hours, transfer 10 µl/well of 200nM IGF-1 Ligand in PBS to the cells (Final Conc. = 20 nM), and incubate at 5% CO₂ at 37°C for 10 minutes.

10 5. Remove media and add 100µl/well HNTG* and shake for 10 minutes. Look at cells under microscope to see if they are adequately lysed.

15 6. Use a 12-channel pipette to scrape the cells from the plate, and homogenize the lysate by repeated aspiration and dispensing. Transfer all the lysate to the antibody coated ELISA plate, and shake for 1 hour.

7. Remove the lysate, wash the plate, transfer anti-pTyr (1:3,000 with TBST) 100 µl/well, and shake for 30 minutes.

20 8. Remove anti-pTyr, wash the plate, transfer TAGO (1:3,000 with TBST) 100 µl/well, and shake for 30 minutes.

9. Remove detection antibody, wash the plate, and transfer fresh ABTS/H₂O₂ (1.2 µl H₂O₂ to 10 ml ABTS) 100 µl/well to the plate to start color development.

10. Measure OD at 410 nm with a reference wavelength of 630 nm in Dynatec MR5000.

e. EGF Receptor ELISA

5 EGF Receptor kinase activity in cells genetically engineered to express human EGF-R can be measured as described below:

Materials and Reagents. The following materials and reagents are used

10 a. EGF Ligand: stock concentration = 16.5 μ M; EGF 201, TOYOB0, Co., Ltd. Japan.

15 b. 05-101 (UBI) (a monoclonal antibody recognizing an EGFR extracellular domain).

c. Anti-phosphotyrosine antibody (anti-Ptyr) (polyclonal).

20 d. Detection antibody: Goat anti-rabbit IgG horse radish peroxidase conjugate, TAGO, Inc., Burlingame, CA.

e. TBST buffer:

25	Tris-HCl, pH 7	50 mM
	NaCl	150 mM
	Triton X-100	0.1

f. HNTG 5X stock:

30	HEPES	0.1 M
	NaCl	0.75 M
	Glycerol	50
	Triton X-100	1.0%

35 g. ABTS stock:

40	Citric Acid	100 mM
	Na ₂ HPO ₄	250 mM
	HCl, conc.	4.0 pH
	ABTS*	0.5 mg/ml

Keep solution in dark at 4°C until used.

h. Stock reagents of:

5 EDTA 100 mM pH 7.0
 Na₃VO₄ 0.5 M
 Na₄(P₂O₇) 0.2 M

Procedure. The following protocol is used:

A. Pre-coat ELISA Plate

10 1. Coat ELISA plates (Corning, 96 well, Cat. #25805-96) with 05-101 antibody at 0.5 µg per well in PBS, 150 µl final volume/well, and store overnight at 4°C. Coated plates are good for up to 10 days when stored at 4°C.

15 2. On day of use, remove coating buffer and replace with blocking buffer (5% Carnation Instant NonFat Dry Milk in PBS). Incubate the plate, shaking, at room temperature (about 23°C to 25°C) for 30 minutes. Just prior to use, remove blocking buffer and wash plate 4 times with TBST buffer.

B. Seeding Cells

20 1. NIH 3T3/C7 cell line (Honegger, et al., Cell 51:199-209, 1987) can be use for this assay.

25 2. Choose dishes having 80-90% confluence for the experiment. Trypsinize cells and stop reaction by adding 10% CS DMEM medium. Suspend cells in DMEM medium (10% CS DMEM medium) and centrifuge once at 1000 rpm at room temperature for 5 minutes.

3. Resuspend cells in seeding medium (DMEM, 0.5% bovine serum), and count the cells using trypan blue. Viability above 90% is acceptable. Seed cells in DMEM medium (0.5% bovine

serum) at a density of 10,000 cells per well, 100 μ l per well, in a 96 well microtiter plate. Incubate seeded cells in 5% CO₂ at 37°C for about 40 hours.

C. Assay Procedures.

5 1. Check seeded cells for contamination using an inverted microscope. Dilute drug stock (10 mg/ml in DMSO) 1:10 in DMEM medium, then transfer 5 μ l to a test well for a final drug dilution of 1:200 and a final DMSO concentration of 1%. Control wells receive DMSO alone. Incubate in 5% CO₂ at 37°C for 10 one hour.

2. Prepare EGF ligand: dilute stock EGF in DMEM so that upon transfer of 10 μ l dilute EGF (1:12 dilution), 25 nM final concentration is attained.

3. Prepare fresh 10 ml HNTG* sufficient for 100 μ l 15 per well wherein HNTG* comprises: HNTG stock (2.0 ml), milli-Q H₂O (7.3 ml), EDTA, 100 mM, pH 7.0 (0.5 ml), Na₃VO₄ 0.5 M (0.1 ml) and Na₄(P₂O₇), 0.2 M (0.1 ml).

4. Place on ice.

5. After two hours incubation with drug, add 20 prepared EGF ligand to cells, 10 μ l per well, to yield a final concentration of 25 nM. Control wells receive DMEM alone. Incubate, shaking, at room temperature, for 5 minutes.

6. Remove drug, EGF, and DMEM. Wash cells twice with PBS. Transfer HNTG* to cells, 100 μ l per well. Place on 25 ice for 5 minutes. Meanwhile, remove blocking buffer from

other ELISA plate and wash with TBST as described above.

7. With a pipette tip securely fitted to a micropipettor, scrape cells from plate and homogenize cell material by repeatedly aspirating and dispensing the HNTG* lysis buffer. Transfer lysate to a coated, blocked, and washed ELISA plate. Incubate shaking at room temperature for one hour.

8. Remove lysate and wash 4 times with TBST. Transfer freshly diluted anti-Ptyr antibody to ELISA plate at 100 μ l per well. Incubate shaking at room temperature for 30 minutes in the presence of the anti-Ptyr antiserum (1:3000 dilution in TBST).

9. Remove the anti-Ptyr antibody and wash 4 times with TBST. Transfer the freshly diluted TAGO 30 anti-rabbit IgG antibody to the ELISA plate at 100 μ l per well. Incubate shaking at room temperature for 30 minutes (anti-rabbit IgG antibody: 1:3000 dilution in TBST).

10. Remove detection antibody and wash 4 times with TBST. Transfer freshly prepared ABTS/H₂O₂ solution to ELISA plate, 100 μ l per well. Incubate at room temperature for 20 minutes. ABTS/H₂O₂ solution: 1.2 μ l 30% H₂O₂ in 10 ml ABTS stock.

11. Stop reaction by adding 50 μ l 5N H₂SO₄ (optional), and determine O.D. at 410 nm.

12. The maximal phosphotyrosine signal is determined by subtracting the value of the negative controls from the positive controls. The percent inhibition of

phosphotyrosine content for extract-containing wells is then calculated, after subtraction of the negative controls.

f. Met Autophosphorylation Assay - ELISA

5 This assay determines Met tyrosine kinase activity by analyzing Met protein tyrosine kinase levels on the Met receptor.

1. Reagents

a. HNTG (5X stock solution): Dissolve 23.83 g HEPES and 43.83 g NaCl in about 350 ml dH₂O. Adjust pH 10 to 7.2 with HCl or NaOH, add 500 ml glycerol and 10 ml Triton X-100, mix, add dH₂O to 1 L total volume.

To make 1 L of 1X working solution add 200 ml 5X stock solution to 800 ml dH₂O, check and adjust pH as necessary, store at 4°C.

b. PBS (Dulbecco's Phosphate-Buffered Saline), Gibco Cat. # 450-1300EB (1X solution).

c. Blocking Buffer: in 500 ml dH₂O place 100 g BSA, 12.1 g Tris-pH7.5, 58.44 g NaCl and 10 ml Tween-20, dilute to 1 L total volume.

d. Kinase Buffer: To 500 ml dH₂O add 12.1 g TRIS pH7.2, 58.4 g NaCl, 40.7 g MgCl₂, and 1.9 g EGTA; bring to 1 L total volume with dH₂O.

e. PMSF (Phenylmethylsulfonyl fluoride), Sigma Cat. # P-7626, to 435.5 mg, add 100% ethanol to 25 ml total volume, vortex.

f. ATP (Bacterial Source), Sigma Cat. # A-7699, store powder at -20°C; to make up solution for use, dissolve 3.31 mg in 1 ml dH₂O.

5 g. RC-20H HRPO Conjugated Anti-Phosphotyrosine, Transduction Laboratories Cat. # E120H.

h. Pierce 1-Step (TM) Turbo TMB-ELISA (3,3',5,5'-tetramethylbenzidine, Pierce Cat. # 34022.

i. H₂SO₄, add 1 ml conc. (18N) to 35 ml dH₂O.

j. TRIS HCL, Fischer Cat. # BP152-5; to 121.14 g of material, add 600 ml MilliQ H₂O, adjust pH to 7.5 (or 7.2) with HCl , bring volume to 1 L with MilliQ H₂O.

10 k. NaCl, Fischer Cat. # S271-10, make up 5M solution.

l. Tween-20, Fischer Cat. # S337-500.

15 m. Na₃VO₄, Fischer Cat. # S454-50, to 1.8 g material add 80 ml MilliQ H₂O, adjust pH to 10.0 with HCl or NaOH, boil in microwave, cool, check pH, repeat procedure until pH stable at 10.0, add MilliQ H₂O to 100 ml total volume, make 1 ml aliquots and store at -80°C.

20 n. MgCl₂, Fischer Cat. # M33-500, make up 1M solution.

o. HEPES, Fischer Cat. # BP310-500, to 200 ml MilliQ H₂O, add 59.6 g material, adjust pH to 7.5, bring volume to 250 ml total, sterile filter.

25 p. Albumin, Bovine (BSA), Sigma Cat. # A-4503, to 30 grams material add sterile distilled water to make

total volume of 300 ml, store at 4°C.

q. TBST Buffer: to approx. 900 ml dH₂O in a 1 L graduated cylinder add 6.057 g TRIS and 8.766 g NaCl, when dissolved, adjust pH to 7.2 with HCl,

5 add 1.0 ml Triton X-100 and bring to 1 L total volume with dH₂O.

r. Goat Affinity purified antibody Rabbit IgG (whole molecule), Cappel Cat. # 55641.

s. Anti h-Met (C-28) rabbit polyclonal IgG antibody, 10 Santa Cruz Chemical Cat. # SC-161.

t. Transiently Transfected EGFR/Met chimeric cells (EMR) (Komada, et al., Oncogene, 8:2381-2390 (1993)).

15 u. Sodium Carbonate Buffer, (Na₂CO₃, Fischer Cat. # S495): to 10.6 g material add 800 ml MilliQ H₂O, when dissolved adjust pH to 9.6 with NaOH, bring up to 1 L total volume with MilliQ H₂O, filter, store at 4°C.

2. Procedure

All of the following steps are conducted at room

20 temperature unless it is specifically indicated otherwise. All ELISA plate washing is by rinsing 4X with TBST.

A. EMR Lysis

This procedure can be performed the night before or immediately prior to the start of receptor capture.

25 1. Quick thaw lysates in a 37°C waterbath with a

swirling motion until the last crystals disappear.

2. Lyse cell pellet with 1X HNTG containing 1 mM PMSF. Use 3 ml of HNTG per 15 cm dish of cells. Add 1/2 the calculated HNTG volume, vortex the tube for 1 min., add the remaining amount of HNTG, vortex for another min.
- 5 3. Balance tubes, centrifuge at 10,000x g for 10 min at 4°C.
- 10 4. Pool supernatants, remove an aliquot for protein determination.
- 15 5. Quick freeze pooled sample in dry ice/ethanol bath. This step is performed regardless of whether lysate will be stored overnight or used immediately following protein determination.
- 20 6. Perform protein determination using standard bicinchoninic acid (BCA) method (BCA Assay Reagent Kit from Pierce Chemical Cat. # 23225).

B. ELISA Procedure

1. Coat Corning 96 well ELISA plates with 5 µg per well Goat anti-Rabbit antibody in Carbonate Buffer for a total well volume of 50

μl. Store overnight at 4°C.

2. Remove unbound Goat anti-rabbit antibody by inverting plate to remove liquid.

3. Add 150 μl of Blocking Buffer to each well.

5 Incubate for 30 min. at room temperature with shaking.

4. Wash 4X with TBST. Pat plate on a paper towel to remove excess liquid and bubbles.

5. Add 1μg per well of Rabbit anti-Met antibody diluted in TBST for a total well volume of 100 μl.

6. Dilute lysate in HNTG (90 μg lysate/100μl)

7. Add 100 μl of diluted lysate to each well. Shake at room temperature for 60 min.

8. Wash 4X with TBST. Pat on paper towel to remove excess liquid and bubbles.

9. Add 50 μl of 1X lysate buffer per well.

10. Dilute compounds/extracts 1:10 in 1X Kinase Buffer in a polypropylene 96 well plate.

15 20 11. Transfer 5.5 μl of diluted drug to ELISA plate wells. Incubate at room temperature with shaking for 20 min.

12. Add 5.5 μl of 60 μM ATP solution per well. Negative controls do not receive any ATP.

25 Incubate at room temperature for 90 min., with

shaking.

13. Wash 4X with TBST. Pat plate on paper towel to remove excess liquid and bubbles.
- 5 14. Add 100 μ l per well of RC20 (1:3000 dilution in Blocking Buffer). Incubate 30 min. at room temperature with shaking.
15. Wash 4X with TBST. Pat plate on paper towel to remove excess liquid and bubbles.
- 10 16. Add 100 μ l per well of Turbo-TMB. Incubate with shaking for 30-60 min.
17. Add 100 μ l per well of 1M H_2SO_4 to stop reaction.
18. Read assay on Dynatech MR7000 ELISA reader. Test Filter = 450 nm, reference filter = 410 nm.

15 g. Biochemical src assay - ELISA

This assay is used to determine src protein kinase activity measuring phosphorylation of a biotinylated peptide as 20 the readout.

1. Materials and Reagents:

- a. Yeast transformed with src from Courtneidge Laboratory (Sugen, Inc., Redwood City, California).
- b. Cell lysates: Yeast cells expressing src are pelleted, washed once with water, re-pelleted and

stored at -80°C until use.

- c. N-terminus biotinylated EEEYEEYEEEYEEYEEEY is prepared by standard procedures well known to those skilled in the art.
- 5 d. DMSO: Sigma, St. Louis, MO.
- e. 96 Well ELISA Plate: Corning 96 Well Easy Wash, Modified flat Bottom Plate, Corning Cat. #25805-96.
- f. NUNC 96-well V-bottom polypropylene plates for dilution of compounds: Applied Scientific Cat. #
- 10 A-72092.
- g. Vecastain ELITE ABC reagent: Vector, Burlingame, CA.
- h. Anti-src (327) mab: Schizosaccharomyces Pombe is used to express recombinant Src (Superti-Furga, et al., EMBO J., 12:2625-2634; Superti-Furga, et al., Nature Biochem., 14:600-605). S. Pombe strain SP200 (h-s leul.32 ura4 ade210) is grown as described and transformations are pRSP expression plasmids are done by the lithium acetate method (Superti-Furga, supra). Cells are grown in the presence of 1 µM thiamine to repress expression from the nmt1 promoter or in the absence of thiamine to induce expression.
- 15 i. Monoclonal anti-phosphotyrosine, UBI 05-321 (UB40 may be used instead).
- 20 j. Turbo TMB-ELISA peroxidase substrate: Pierce

Chemical.

2. Buffer Solutions:

- a. PBS (Dulbecco's Phosphate-Buffered Saline): GIBCO PBS, GIBCO Cat. # 450-1300EB.
- 5 b. Blocking Buffer: 5% Non-fat milk (Carnation) in PBS.
- c. Carbonate Buffer: Na_2CO_3 from Fischer, Cat. # S495, make up 100 mM stock solution.
- 10 d. Kinase Buffer: 1.0 ml (from 1M stock solution) MgCl_2 ; 0.2 ml (from a 1M stock solution) MnCl_2 ; 0.2 ml (from a 1M stock solution) DTT; 5.0 ml (from a 1M stock solution) HEPES; 0.1 ml TX-100; bring to 10 ml total volume with MilliQ H_2O .
- 15 e. Lysis Buffer: 5.0 HEPES (from 1M stock solution.); 2.74 ml NaCl (from 5M stock solution); 10 ml glycerol; 1.0 ml TX-100; 0.4 ml EDTA (from a 100 mM stock solution); 1.0 ml PMSF (from a 100 mM stock solution); 0.1 ml Na_3VO_4 (from a 0.1 M stock solution); bring to 100 ml total volume with MilliQ H_2O .
- 20 f. ATP: Sigma Cat. # A-7699, make up 10 mM stock solution (5.51 mg/ml).
- g. TRIS-HCl: Fischer Cat. # BP 152-5, to 600 ml MilliQ H_2O add 121.14 g material, adjust pH to 7.5 with HCl, bring to 1 L total volume with MilliQ H_2O .

h. NaCl: Fischer Cat. # S271-10, Make up 5M stock solution with MilliQ H₂O.

i. Na₃VO₄: Fischer Cat. # S454-50; to 80 ml MilliQ H₂O, add 1.8 g material; adjust pH to 10.0 with HCl or NaOH; boil in a microwave; cool; check pH, repeat pH adjustment until pH remains stable after heating/cooling cycle; bring to 100 ml total volume with MilliQ H₂O; make 1 ml aliquots and store at -80°C.

j. MgCl₂: Fischer Cat. # M33-500, make up 1M stock solution with MilliQ H₂O.

k. HEPES: Fischer Cat. # BP 310-500; to 200 ml MilliQ H₂O, add 59.6 g material, adjust pH to 7.5, bring to 250 ml total volume with MilliQ H₂O, sterile filter (1M stock solution).

l. TBST Buffer: TBST Buffer: To 900 ml dH₂O add 6.057 g TRIS and 8.766 g NaCl; adjust pH to 7.2 with HCl, add 1.0 ml Triton-X100; bring to 1 L total volume with dH₂O.

m. MnCl₂: Fischer Cat. # M87-100, make up 1M stock solution with MilliQ H₂O.

n. DTT: Fischer Cat. # BP172-5.

o. TBS (TRIS Buffered Saline): to 900 ml MilliQ H₂O add 6.057 g TRIS and 8.777 g NaCl; bring to 1 L total volume with MilliQ H₂O.

p. Kinase Reaction Mixture: Amount per assay plate (100 wells): 1.0 ml Kinase Buffer, 200 µg GST- ζ ,

bring to final volume of 8.0 ml with MilliQ H₂O.

q. Biotin labeled EEEYEYEEYEYEEYEY: Make peptide stock solution (1mM, 2.98 mg/ml) in water fresh just before use.

5 r. Vectastain ELITE ABC reagent: To prepare 14 ml of working reagent, add 1 drop of reagent A to 15 ml TBST and invert tube several times to mix. Then add 1 drop of reagent B. Put tube on orbital shaker at room temperature and mix for 30 minutes.

10

3. Procedures:

a. Preparation of src coated ELISA plate.

1. Coat ELISA plate with 0.5 μ g/well anti-src mab in 100 μ l of pH 9.6 sodium carbonate buffer at 15 4°C overnight.

2. Wash wells once with PBS.

3. Block plate with 0.15 ml 5% milk in PBS for 30 min. at room temperature.

4. Wash plate 5X with PBS.

20 5. Add 10 μ g/well of src transformed yeast lysates diluted in Lysis Buffer (0.1 ml total volume per well). (Amount of lysate may vary between batches.) Shake plate for 20 minutes at room temperature.

25 b. Preparation of phosphotyrosine antibody-coated

ELISA plate.

1. 4G10 plate: coat 0.5 μ g/well 4G10 in 100 μ l PBS overnight at 4°C and block with 150 μ l of 5% milk in PBS for 30 minutes at room 5 temperature.

c. Kinase assay procedure.

1. Remove unbound proteins from step 1-7, above, and wash plates 5X with PBS.
2. Add 0.08 ml Kinase Reaction Mixture per well (containing 10 μ l of 10X Kinase Buffer and 10 μ M (final concentration) biotin-EEYEYEEYEYEEYEY per well diluted in water.
3. Add 10 μ l of compound diluted in water containing 10% DMSO and pre-incubate for 15 minutes at room temperature.
4. Start kinase reaction by adding 10 μ l/well of 0.05 mM ATP in water (5 μ M ATP final).
5. Shake ELISA plate for 15 min. at room temperature.
6. Stop kinase reaction by adding 10 μ l of 0.5 M EDTA per well.
7. Transfer 90 μ l supernatant to a blocked 4G10 coated ELISA plate from section B, above.
8. Incubate for 30 min. while shaking at room 25 temperature.

9. Wash plate 5X with TBST.
10. Incubate with Vectastain ELITE ABC reagent (100 μ l/well) for 30 min. at room temperature.
11. Wash the wells 5X with TBST.
- 5 12. Develop with Turbo TMB.

h. Biochemical lck Assay - ELISA

This assay is used to determine lck protein kinase activities measuring phosphorylation of GST- ζ as the readout.

10 1. Materials and Reagents:

a. Yeast transformed with lck. *Schizosaccharomyces Pombe* is used to express recombinant Lck (Superti-Furga, et al., EMBO J, 12:2625-2634; Superti-Furga, et al., Nature Biotech., 14:600-605). *S. Pombe*

15 strain SP200 (h-s leul.32 ura4 ade210) is grown as described and transformations with pRSP expression plasmids are done by the lithium acetate method (Superti-Furga, supra). Cells are grown in the presence of 1 μ M thiamine to induce expression.

20 b. Cell lysates: Yeast cells expressing lck are pelleted, washed once in water, re-pelleted and stored frozen at -80°C until use.

c. GST- ζ : DNA encoding for GST- ζ fusion protein for expression in bacteria obtained from Arthur Weiss of the Howard Hughes Medical Institute at the

University of California, San Francisco.

Transformed bacteria are grown overnight while shaking at 25°C. GST- ζ is purified by glutathione affinity chromatography, Pharmacia, Alameda, CA.

5 d. DMSO: Sigma, St. Louis, MO.

 e. 96-Well ELISA plate: Corning 96 Well Easy Wash, Modified Flat Bottom Plate, Corning Cat. #25805-96.

 f. NUNC 96-well V-bottom polypropylene plates for dilution of compounds: Applied Scientific Cat. # AS-72092.

10 g. Purified Rabbit anti-GST antiserum: Amrad Corporation (Australia) Cat. #90001605.

 h. Goat anti-Rabbit-IgG-HRP: Amersham Cat. # V010301.

 i. Sheep ant-mouse IgG (H+L): Jackson Labs Cat. # 5215-005-003.

15 j. Anti-Lck (3A5) mab: Santa Cruz Biotechnology Cat # sc-433.

 k. Monoclonal anti-phosphotyrosine UBI 05-321 (UB40 may be used instead).

20 2. Buffer solutions:

 a. PBS (Dulbecco's Phosphate-Buffered Saline) 1X solution: GIBCO PBS, GIBCO Cat. # 450-1300EB.

 b. Blocking Buffer: 100 g. BSA, 12.1 g. TRIS-pH7.5, 25 58.44 g NaCl, 10 ml Tween-20, bring up to 1 L total volume with MilliQ H₂O.

- c. Carbonate Buffer: Na_2CO_3 from Fischer, Cat. # S495; make up 100 mM solution with MilliQ H_2O .
- d. Kinase Buffer: 1.0 ml (from 1M stock solution) MgCl_2 ; 0.2 ml (from a 1M stock solution) MnCl_2 ; 0.2 ml (from a 1M stock solution) DTT; 5.0 ml (from a 1M stock solution) HEPES; 0.1 ml TX-100; bring to 10 ml total volume with MilliQ H_2O .
- e. Lysis Buffer: 5.0 HEPES (from 1M stock solution.); 2.74 ml NaCl (from 5M stock solution); 10 ml glycerol; 1.0 ml TX-100; 0.4 ml EDTA (from a 100 mM stock solution); 1.0 ml PMSF (from a 100 mM stock solution); 0.1 ml Na_3VO_4 (from a 0.1 M stock solution); bring to 100 ml total volume with MilliQ H_2O .
- f. ATP: Sigma Cat. # A-7699, make up 10 mM stock solution (5.51 mg/ml).
- g. TRIS-HCl: Fischer Cat. # BP 152-5, to 600 ml MilliQ H_2O add 121.14 g material, adjust pH to 7.5 with HCl, bring to 1 L total volume with MilliQ H_2O .
- h. NaCl: Fischer Cat. # S271-10, Make up 5M stock solution with MilliQ H_2O .
- i. Na_3VO_4 : Fischer Cat. # S454-50; to 80 ml MilliQ H_2O , add 1.8 g material; adjust pH to 10.0 with HCl or NaOH; boil in a microwave; cool; check pH, repeat pH adjustment until pH remains stable after

heating/cooling cycle; bring to 100 ml total volume with MilliQ H₂O; make 1 ml aliquots and store at -80°C.

- j. MgCl₂: Fischer Cat. # M33-500, make up 1M stock solution with MilliQ H₂O.
- 5 k. HEPES: Fischer Cat. # BP 310-500; to 200 ml MilliQ H₂O, add 59.6 g material, adjust pH to 7.5, bring to 250 ml total volume with MilliQ H₂O, sterile filter (1M stock solution).
- 10 l. Albumin, Bovine (BSA), Sigma Cat. # A4503; to 150 ml MilliQ H₂O add 30 g material, bring 300 ml total volume with MilliQ H₂O, filter through 0.22 µm filter, store at 4°C.
- m. TBST Buffer: To 900 ml dH₂O add 6.057 g TRIS and 8.766 g NaCl; adjust pH to 7.2 with HCl, add 1.0 ml Triton-X100; bring to 1 L total volume with dH₂O.
- 15 n. MnCl₂: Fischer Cat. # M87-100, make up 1M stock solution with MilliQ H₂O.
- o. DTT; Fischer Cat. # BP172-5.
- 20 p. TBS (TRIS Buffered Saline): to 900 ml MilliQ H₂O add 6.057 g TRIS and 8.777 g NaCl; bring to 1 L total volume with MilliQ H₂O.
- q. Kinase Reaction Mixture: Amount per assay plate (100 wells): 1.0 ml Kinase Buffer, 200 µg GST-ζ, bring to final volume of 8.0 ml with MilliQ H₂O.

2. Procedures:

a. Preparation of Lck coated ELISA plate.

1. Coat 2.0 μ g/well Sheep anti-mouse IgG in 100 μ l of pH 9.6 sodium carbonate buffer at 4°C overnight.

5 2. Wash well once with PBS.

3. Block plate with 0.15 ml of blocking Buffer for 30 min. at room temp.

4. Wash plate 5X with PBS.

10 5. Add 0.5 μ g/well of anti-lck (mab 3A5) in 0.1 ml PBS at room temperature for 1-2 hours.

6. Wash plate 5X with PBS.

7. Add 20 μ g/well of lck transformed yeast lysates diluted in Lysis Buffer (0.1 ml total volume per well).

15 (Amount of lysate may vary between batches) Shake plate at 4°C overnight to prevent loss of activity.

b. Preparation of phosphotyrosine antibody-coated ELISA plate.

20 1. UB40 plate: 1.0 μ g/well UB40 in 100 μ l of PBS overnight at 4°C and block with 150 μ l of Blocking Buffer for at least 1 hour.

c. Kinase assay procedure.

1. Remove unbound proteins from step 1-7, above, and wash plates 5X with PBS.

25 2. Add 0.08 ml Kinase Reaction Mixture per well (containing 10 μ l of 10X Kinase Buffer and 2 μ g GST- ζ per well

diluted with water).

3. Add 10 μ l of compound diluted in water containing 10% DMSO and pre-incubate for 15 minutes at room temperature.

5 4. Start kinase reaction by adding 10 μ l/well of 0.1 mM ATP in water (10 μ M ATP final).

5. Shake ELISA plate for 60 min. at room temperature.

6. Stop kinase reaction by adding 10 μ l of 0.5 M 10 EDTA per well.

7. Transfer 90 μ l supernatant to a blocked 4G10 coated ELISA plate from section B, above.

8. Incubate while shaking for 30 min. at room temperature.

15 9. Wash plate 5X with TBST.

10. Incubate with Rabbit anti-GST antibody at 1:5000 dilution in 100 μ l TBST for 30 min. at room temperature.

11. Wash the wells 5X with TBST.

12. Incubate with Goat anti-Rabbit-IgG-HRP at 20 1:20,000 dilution in 100 μ l of TBST for 30 min. at room temperature.

13. Wash the wells 5X with TBST.

14. Develop with Turbo TMB.

i. ASSAY MEASURING PHOSPHORYLATING FUNCTION
OF RAF

The following assay reports the amount of RAF-catalyzed phosphorylation of its target protein MEK as well as MEK's target MAPK. The RAF gene sequence is described in Bonner et al., 1985, Molec. Cell. Biol. 5: 1400-1407, and is readily accessible in multiple gene sequence data banks. Construction of the nucleic acid vector and cell lines utilized for this portion of the invention are fully described in Morrison et al., 1988, Proc. Natl. Acad. Sci. USA 85: 8855-8859.

Materials and Reagents

1. *Sf9* (*Spodoptera frugiperda*) cells; GIBCO-BRL, Gaithersburg, MD.
- 15 2. RIPA buffer: 20 mM Tris/HCl pH 7.4, 137 mM NaCl, 10% glycerol, 1 mM PMSF, 5 mg/L Aprotinin, 0.5 % Triton X-100;
3. Thioredoxin-MEK fusion protein (T-MEK): T-MEK expression and purification by affinity chromatography are performed according to the manufacturer's procedures. Catalog# 20 K 350-01 and R 350-40, Invitrogen Corp., San Diego, CA
4. His-MAPK (ERK 2); His-tagged MAPK is expressed in XL1 Blue cells transformed with pUC18 vector encoding His-MAPK. His-MAPK is purified by Ni-affinity chromatography. Cat# 27-4949-01, Pharmacia, Alameda, CA, as described herein.
- 25 5. Sheep anti mouse IgG: Jackson laboratories, West Grove, PA. Catalog, # 515-006-008, Lot# 28563

6. RAF-1 protein kinase specific antibody: URP2653 from UBI.

7. Coating buffer: PBS; phosphate buffered saline, GIBCO-BRL, Gaithersburg, MD.

5 8. Wash buffer: TBST - 50 mM Tris/HCL pH 7.2, 150 mM NaCl, 0.1 % Triton X-100

9. Block buffer: TBST, 0.1 % ethanolamine pH 7.4

10. DMSO, Sigma, St. Louis, MO

11. Kinase buffer (KB): 20 mM HEPES/HCl pH 7.2, 150 mM NaCl, 0.1 % Triton X-100, 1 mM PMSF, 5 mg/L Aprotinin, 75 mM sodium ortho vanadate, 0.5 MM DTT and 10 mM MgCl₂.

12. ATP mix: 100 mM MgCl₂, 300 mM ATP, 10 mCi ³³P ATP (Dupont-NEN) /mL.

13 Stop solution: 1 % phosphoric acid, Fisher, 15 Pittsburgh, PA.

14. Wallac Cellulose Phosphate Filter mats, Wallac, Turku, Finnland.

15. Filter wash solution: 1 % phosphoric acid, Fisher, Pittsburgh, PA.

20 16. Tomtec plate harvester, Wallac, Turku, Finnland.

17. Wallac beta plate reader # 1205, Wallac, Turku, Finnland.

18. NUNC 96-well V bottom polypropylene plates for compounds Applied Scientific Catalog # AS-72092.

All of the following steps are conducted at room temperature unless specifically indicated.

1. ELISA plate coating: ELISA wells are coated with 100 ml of Sheep anti mouse affinity purified antiserum (1 5 mg/100 mL coating buffer) over night at 4 °C. ELISA plates can be used for two weeks when stored at 4 °C.

2. Invert the plate and remove liquid. Add 100 mL of blocking solution and incubate for 30 min.

3. Remove blocking solution and wash four times with 10 wash buffer. Pat the plate on a paper towel to remove excess liquid.

4. Add 1 mg of antibody specific for RAF-1 to each well and incubate for 1 hour. Wash as described in step 3.

5. Thaw lysates from RAS/RAF infected Sf9 cells and 15 dilute with TBST to 10 mg/100 mL. Add 10 mg of diluted lysate to the wells and incubate for 1 hour. Shake the plate during incubation. Negative controls receive no lysate. Lysates from RAS/RAF infected Sf9 insect cells are prepared after cells are infected with recombinant baculoviruses at a MOI of 5 for each 20 virus, and harvested 48 hours later. The cells are washed once with PBS and lysed in RIPA buffer. Insoluble material is removed by centrifugation (5 min at 10 000 x g). Aliquots of lysates are frozen in dry ice/ethanol and stored at -80 °C until use.

25 6. Remove non-bound material and wash as outlined

above (step 3).

7. Add 2 mg of T-MEK and 2 mg of His-MAEPK per well and adjust the volume to 40 mL with kinase buffer. Methods for purifying T-MEK and MAPK from cell extracts are provided herein 5 by example.

8. Pre-dilute compounds (stock solution 10 mg/mL DMSO) or extracts 20 fold in TBST plus 1% DMSO. Add 5 mL of the pre-diluted compounds/extracts to the wells described in step 6. Incubate for 20 min. Controls receive no drug.

10 9. Start the kinase reaction by addition of 5 mL ATP mix; Shake the plates on an ELISA plate shaker during incubation. 10. Stop the kinase reaction after 60 min by addition of 30 mL stop solution to each well.

11. Place the phosphocellulose mat and the ELISA plate 15 in the Tomtec plate harvester. Harvest and wash the filter with the filter wash solution according to the manufacturers recommendation. Dry the filter mats. Seal the filter mats and place them in the holder. Insert the holder into radioactive detection apparatus and quantify the radioactive phosphorous on 20 the filter mats.

Alternatively, 40 mL aliquots from individual wells of the assay plate can be transferred to the corresponding positions on the phosphocellulose filter mat. After air drying the filters, put the filters in a tray. Gently rock the tray, 25 changing the wash solution at 15 min intervals for 1 hour. Air-dry the filter mats. Seal the filter mats and place them

in a holder suitable for measuring the radioactive phosphorous in the samples. Insert the holder into a detection device and quantify the radioactive phosphorous on the filter mats.

j. CDK2/Cyclin A - Inhibition Assay

5 This assay analyzes the protein kinase activity of CDK2 in exogenous substrate.

Reagents:

A. Buffer A (80 mM Tris (pH 7.2), 40 mM MgCl₂): 4.84 G.
Tris (F.W. =121.1 g/mol), 4.07 g. MgCl₂ (F.W.=203.31

10 g/mol) dissolved in 500 ml H₂O. Adjust pH to 7.2 with HCl.

B. Histone H1 solution (0.45 mg/ml Histone H1 and 20 mM HEPES pH 7.2 (pH 7.4 is OK): 5 mg Histone H1 (Boehringer Mannheim) in 11.111 ml 20 mM HEPES pH 7.2 (477 mg HEPES 15 (F.W.= 238.3 g/mol) dissolved in 100 ml ddH₂O, stored in 1 ml aliquots at -80° C.

C. ATP solution (60 μM ATP, 300 μg/ml BSA, 3 mM DTT): 120 μl 10 mM ATP, 600 μl 10 mg/ml BSA to 20 ml, stored in 1 ml aliquots at -80° C.

20 D. CDK2 solution: cdk2/cyclin A in 10 mM HEPES pH 7.2, 25 mM NaCl, 0.5 mM DTT, 10% glycerol, stored in 9 μl aliquots at -80° C.

Description of Assay:

25 1. Prepare solutions of inhibitors at three times the desired final assay concentration in ddH₂O/15 % DMSO by

volume.

2. Dispense 20 μ l of inhibitors to wells of polypropylene 96-well plates (or 20 μ l 15% DMSO for positive and negative controls).
- 5 3. Thaw Histone H1 solution (1 ml/plate), ATP solution (1 ml/plate plus 1 aliquot for negative control), and CDK2 solution (9 μ l/plate). Keep CDK2 on ice until use. Aliquot CDK2 solution appropriately to avoid repeated freeze-thaw cycles.
- 10 4. Dilute 9 μ l CDK2 solution into 2.1 ml Buffer A (per plate). Mix. Dispense 20 μ l into each well.
5. Mix 1 ml Histone H1 solution with 1 ml ATP solution (per plate) into a 10 ml screw cap tube. Add γ^{33} P ATP to a concentration of 0.15 μ Ci/20 μ l (0.15 μ Ci/well in assay).
- 15 Mix carefully to avoid BSA frothing. Add 20 μ l to appropriate wells. Mix plates on plate shaker. For negative control, mix ATP solution with an equal amount of 20 mM HEPES pH 7.2 and add γ^{33} P ATP to a concentration of 0.15 μ Ci/20 μ l solution. Add 20 μ l to appropriate wells.
- 20 6. Let reactions proceed for 60 minutes.
7. Add 35 μ l 10% TCA to each well. Mix plates on plate shaker.
8. Spot 40 μ l of each sample onto P30 filter mat squares.

Allow mats to dry (approx. 10-20 minutes).

9 Wash filter mats 4 X 10 minutes with 250 ml 1% phosphoric acid (10 ml phosphoric acid per liter ddH₂O).

10. Count filter mats with beta plate reader.

5 2. Cellular/Biologic Assays

Assay 1: PDGF-Induced BrdU Incorporation

Assay

Materials and Reagents:

(1) PDGF: human PDGF B/B; 1276-956, Boehringer 10 Mannheim, Germany.

(2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

15 (4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer 20 Mannheim, Germany.

(6) PBS Washing Solution : 1X PBS, pH 7.4, made in house (Sugen, Inc., Redwood City, California).

(7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

25 (8) 3T3 cell line genetically engineered to express human PDGF-R.

Protocol

- (1) Cells are seeded at 8000 cells/well in DMEM, 10% CS, 2mM Gln in a 96 well plate. Cells are incubated 5 overnight at 37°C in 5% CO₂.
- (2) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- (3) On day 3, ligand (PDGF, 3.8 nM, prepared in DMEM 10 with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (PDGF) but no test compound. Test compounds are prepared 15 in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.
- (4) After 20 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final 20 concentration=10 µM) for 1.5 hours.
- (5) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added 25 (50 µl/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.

(6) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.

(7) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

(8) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.

(9) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.

(10) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 2: EGF-Induced BrdU Incorporation

Assay

Materials and Reagents

(1) EGF: mouse EGF, 201; Toyobo, Co., Ltd. Japan.

5 (2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

10 (4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

15 (6) PBS Washing Solution : 1X PBS, pH 7.4, made in house (Sugen, Inc., Redwood City, California).

(7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.

(8) 3T3 cell line genetically engineered to express 20 human EGF-R.

Protocol

(1) Cells are seeded at 8000 cells/well in 10% CS, 2mM Gln in DMEM, in a 96 well plate. Cells are 25 incubated overnight at 37°C in 5% CO₂.

- (2) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0% CS DMEM with 0.1% BSA) for 24 hours.
- 5 (3) On day 3, ligand (EGF, 2 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (EGF) but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.
- 10 (4) After 20 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 μ M) for 1.5 hours.
- 15 (5) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.
- 20 (6) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on

a plate shaker.

(7) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

5 (8) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.

10 (9) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.

15 (10) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 3: EGF-Induced Her2-Driven BrdU

20 **Incorporation**

Materials and Reagents:

(1) EGF: mouse EGF, 201; Toyobo, Co., Ltd. Japan

(2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

25 (3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

- (4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- 5 (5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.
- (6) PBS Washing Solution: 1X PBS, pH 7.4, made in house.
- 10 (7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.
- (8) 3T3 cell line engineered to express a chimeric receptor having the extra-cellular domain of EGF-R and the intra-cellular domain of Her2.

Protocol:

- 15 (1) Cells are seeded at 8000 cells/well in DMEM, 10% CS, 2mM Gln in a 96-well plate. Cells are incubated overnight at 37° in 5% CO₂.
- (2) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- 20 (3) On day 3, ligand (EGF=2 nM, prepared in DMEM with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (EGF) but no test compound. Test compounds are prepared in serum free

DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.

- (4) After 20 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration = 10 μ M) for 1.5 hours.
- 5 (5) After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.
- 10 (6) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.
- 15 (7) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.
- 20 (8) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on

a paper towel.

5

(9) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.

10

(10) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

Assay 4: IGF1-Induced BrdU Incorporation

Assay

Materials and Reagents:

15

(1) IGF1 Ligand: human, recombinant; G511, Promega Corp, USA.

(2) BrdU Labeling Reagent: 10 mM, in PBS (pH7.4), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

20

(3) FixDenat: fixation solution (ready to use), Cat. No. 1 647 229, Boehringer Mannheim, Germany.

(4) Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

25

(5) TMB Substrate Solution: tetramethylbenzidine (TMB), ready to use, Cat. No. 1 647 229, Boehringer Mannheim, Germany.

- (6) PBS Washing Solution: 1X PBS, pH 7.4, made in house (Sugen, Inc., Redwood City, California).
- (7) Albumin, Bovine (BSA): fraction V powder; A-8551, Sigma Chemical Co., USA.
- 5 (8) 3T3 cell line genetically engineered to express human IGF-1 receptor.

Protocol:

- (1) Cells are seeded at 8000 cells/well in DMEM, 10% CS, 2mM Gln in a 96- well plate. Cells are 10 incubated overnight at 37°C in 5% CO₂.
- (2) After 24 hours, the cells are washed with PBS, and then are serum starved in serum free medium (0%CS DMEM with 0.1% BSA) for 24 hours.
- (3) On day 3, ligand (IGF1=3.3 nM, prepared in DMEM 15 with 0.1% BSA) and test compounds are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand (IGF1) but no test compound. Test compounds are prepared 20 in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.
- (4) After 16 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added 25 and the cells are incubated with BrdU (final concentration=10 μM) for 1.5 hours.
- (5) After incubation with labeling reagent, the medium

is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.

5 (6) The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.

10 (7) The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

15 (8) The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.

20 (9) TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.

25 (10) The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading

at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

5

g. HUV-EC-C Assay

The following protocol may also be used to measure a compound's activity against PDGF-R, FGF-R, VEGF, aFGF or Flk-1/KDR, all of which are naturally expressed by HUV-EC cells.

10 DAY 0

1. Wash and trypsinize HUV-EC-C cells (human umbilical vein endothelial cells, (American Type Culture Collection; catalogue no. 1730 CRL). Wash with Dulbecco's phosphate-buffered saline (D-PBS; obtained from Gibco BRL; catalogue no. 14190-029) 2 times at about 1 ml/10 cm² of tissue culture flask.

Trypsinize with 0.05% trypsin-EDTA in non-enzymatic cell dissociation solution (Sigma Chemical Company; catalogue no. C-1544). The 0.05% trypsin is made by diluting 0.25% trypsin/1 mM EDTA (Gibco; catalogue no. 25200-049) in the cell dissociation solution. Trypsinize with about 1 ml/25-30 cm² of tissue culture flask for about 5 minutes at 37°C. After cells have detached from the flask, add an equal volume of assay medium and transfer to a 50 ml sterile centrifuge tube (Fisher Scientific; catalogue no. 05-539-6).

25 2. Wash the cells with about 35 ml assay medium in the 50 ml sterile centrifuge tube by adding the assay medium,

centrifuge for 10 minutes at approximately 200 g, aspirate the supernatant, and resuspend with 35 ml D-PBS. Repeat the wash two more times with D-PBS, resuspend the cells in about 1 ml assay medium/15 cm² of tissue culture flask. Assay medium

5 consists of F12K medium (Gibco BRL; catalogue no. 21127-014) + 0.5% heat-inactivated fetal bovine serum. Count the cells with a Coulter Counter, Coulter Electronics, Inc.) and add assay medium to the cells to obtain a concentration of 0.8-1.0x10⁵ cells/ml.

10 3. Add cells to 96-well flat-bottom plates at 100 µl/well or 0.8-1.0x10⁴ cells/well; incubate ~24h at 37°C, 5% CO₂.

DAY 1

15 1. Make up two-fold drug titrations in separate 96-well plates, generally 50 µM on down to 0 µM. Use the same assay medium as mentioned in day 0, step 2 above. Titrations are made by adding 90 µl/well of drug at 200 µM (4X the final well concentration) to the top well of a particular plate column. Since the stock drug concentration is usually 20 mM in

20 DMSO, the 200 µM drug concentration contains 2% DMSO.

Therefore, diluent made up to 2% DMSO in assay medium (F12K + 0.5% fetal bovine serum) is used as diluent for the drug titrations in order to dilute the drug but keep the DMSO concentration constant. Add this diluent to the remaining 25 wells in the column at 60 µl/well. Take 60 µl from the 120 µl

of 200 μ M drug dilution in the top well of the column and mix with the 60 μ l in the second well of the column. Take 60 μ l from this well and mix with the 60 μ l in the third well of the column, and so on until two-fold titrations are completed.

- 5 When the next-to-the-last well is mixed, take 60 μ l of the 120 μ l in this well and discard it. Leave the last well with 60 μ l of DMSO/media diluent as a non-drug-containing control. Make 9 columns of titrated drug, enough for triplicate wells each for
 - 1) VEGF (obtained from Pepro Tech Inc., catalogue no. 100-200,
 - 10 2) endothelial cell growth factor (ECGF) (also known as acidic fibroblast growth factor, or aFGF) (obtained from Boehringer Mannheim Biochemica, catalogue no. 1439 600); or, 3) human PDGF B/B (1276-956, Boehringer Mannheim, Germany) and assay media control. ECGF comes as a preparation with sodium heparin.

- 15 2. Transfer 50 μ l/well of the drug dilutions to the 96-well assay plates containing the $0.8-1.0 \times 10^4$ cells/100 μ l/well of the HUV-EC-C cells from day 0 and incubate ~2 h at 37°C, 5% CO₂.

- 20 3. In triplicate, add 50 μ l/well of 80 μ g/ml VEGF, 20 ng/ml ECGF, or media control to each drug condition. As with the drugs, the growth factor concentrations are 4X the desired final concentration. Use the assay media from day 0 step 2 to make the concentrations of growth factors. Incubate approximately 24 hours at 37°C, 5% CO₂. Each well will have 50 μ l drug dilution, 50 μ l growth factor or media, and 100 μ l

cells, = 200 μ l/well total. Thus the 4X concentrations of drugs and growth factors become 1X once everything has been added to the wells.

DAY 2

5 1. Add 3 H-thymidine (Amersham; catalogue no. TRK-686) at 1 μ Ci/well (10 μ l/well of 100 μ Ci/ml solution made up in RPMI media + 10% heat-inactivated fetal bovine serum) and incubate ~24 h at 37°C, 5% CO₂. RPMI is obtained from Gibco BRL, catalogue no. 11875-051.

10 DAY 3

1. Freeze plates overnight at -20°C.

DAY 4

1. Thaw plates and harvest with a 96-well plate harvester (Tomtec Harvester 96^(R)) onto filter mats (Wallac; catalogue no. 1205-401); read counts on a Wallac Betaplate^(TM) liquid scintillation counter.

3. In Vivo Animal Models

A. Xenograft Animal Models

The ability of human tumors to grow as 20 xenografts in athymic mice (e.g., Balb/c, nu/nu) provides a useful in vivo model for studying the biological response to therapies for human tumors. Since the first successful xenotransplantation of human tumors into athymic mice, (Rygaard and Povlsen, 1969, Acta Pathol. Microbial. Scand. 77:758-760), 25 many different human tumor cell lines (e.g., mammary, lung,

genitourinary, gastro-intestinal, head and neck, glioblastoma, bone, and malignant melanomas) have been transplanted and successfully grown in nude mice. The following assays may be used to determine the level of activity, specificity and effect 5 of the different compounds of the present invention. Three general types of assays are useful for evaluating compounds: cellular/catalytic, cellular/biological and in vivo. The object of the cellular/catalytic assays is to determine the effect of a compound on the ability of a TK to phosphorylate 10 tyrosines on a known substrate in a cell. The object of the cellular/biological assays is to determine the effect of a compound on the biological response stimulated by a TK in a cell. The object of the in vivo assays is to determine the effect of a compound in an animal model of a particular 15 disorder such as cancer.

Suitable cell lines for subcutaneous xenograft experiments include C6 cells (glioma, ATCC # CCL 107), A375 cells (melanoma, ATCC # CRL 1619), A431 cells (epidermoid carcinoma, ATCC # CRL 1555), Calu 6 cells (lung, ATCC # HTB 20 56), PC3 cells (prostate, ATCC # CRL 1435), SKOV3TP5 cells and NIH 3T3 fibroblasts genetically engineered to overexpress EGFR, PDGFR, IGF-1R or any other test kinase. The following protocol can be used to perform xenograft experiments:

Female athymic mice (BALB/c, nu/nu) are obtained from 25 Simonsen Laboratories (Gilroy, CA). All animals are maintained under clean-room conditions in Micro-isolator cages with

Alpha-dri bedding. They receive sterile rodent chow and water ad libitum.

Cell lines are grown in appropriate medium (for example, MEM, DMEM, Ham's F10, or Ham's F12 plus 5% - 10% fetal bovine serum (FBS) and 2 mM glutamine (GLN)). All cell culture media, glutamine, and fetal bovine serum are purchased from Gibco Life Technologies (Grand Island, NY) unless otherwise specified. All cells are grown in a humid atmosphere of 90-95% air and 5-10% CO₂ at 37°C. All cell lines are routinely subcultured twice a week and are negative for mycoplasma as determined by the Mycotect method (Gibco).

Cells are harvested at or near confluency with 0.05% Trypsin-EDTA and pelleted at 450 x g for 10 min. Pellets are resuspended in sterile PBS or media (without FBS) to a particular concentration and the cells are implanted into the hindflank of the mice (8 - 10 mice per group, 2 - 10 x 10⁶ cells/animal). Tumor growth is measured over 3 to 6 weeks using venier calipers. Tumor volumes are calculated as a product of length x width x height unless otherwise indicated. P values are calculated using the Students t-test.

Test compounds in 50 - 100 µL excipient (DMSO, or VPD:D5W) can be delivered by IP injection at different concentrations generally starting at day one after implantation.

B. Tumor Invasion Model

The following tumor invasion model has been developed and may be used for the evaluation of therapeutic

value and efficacy of the compounds identified to selectively inhibit KDR/FLK-1 receptor.

Procedure

8 week old nude mice (female) (Simonsen Inc.) are used as experimental animals. Implantation of tumor cells can be performed in a laminar flow hood. For anesthesia, Xylazine/Ketamine Cocktail (100 mg/kg ketamine and 5 mg/kg Xylazine) are administered intraperitoneally. A midline incision is done to expose the abdominal cavity (approximately 1.5 cm in length) to inject 10^7 tumor cells in a volume of 100 μ l medium. The cells are injected either into the duodenal lobe of the pancreas or under the serosa of the colon. The peritoneum and muscles are closed with a 6-0 silk continuous suture and the skin is closed by using wound clips. Animals are observed daily.

Analysis

After 2-6 weeks, depending on gross observations of the animals, the mice are sacrificed, and the local tumor metastases in various organs (lung, liver, brain, stomach, spleen, heart, muscle) are excised and analyzed (measurement of tumor size, grade of invasion, immunohistochemistry, in situ hybridization, etc.).

D. Measurement Of Cell Toxicity

Therapeutic compounds should be more potent in inhibiting receptor tyrosine kinase activity than in exerting a cytotoxic effect. A measure of the effectiveness and cell

toxicity of a compound can be obtained by determining the therapeutic index: IC_{50}/LD_{50} . IC_{50} , the dose required to achieve 50% inhibition, can be measured using standard techniques such as those described herein. LD_{50} , the dosage which results 5 in 50% toxicity, can also be measured by standard techniques (Mossman, 1983, J. Immunol. Methods, 65:55-63), by measuring the amount of LDH released (Korzeniewski and Callewaert, 1983, J. Immunol. Methods, 64:313; Decker and Lohmann-Matthes, 1988, J. Immunol. Methods, 115:61), or by measuring 10 the lethal dose in animal models. Compounds with a large therapeutic index are preferred. The therapeutic index should be greater than 2, preferably at least 10, more preferably at least 50.

TABLE 3

15

RESULTS OF ASSAYS OF SELECTED COMPOUNDS

NAME	PDGFR KINASE IC_{50} (μM)	FLK KINASE IC_{50} (μM)	EGFR KINASE IC_{50} (μM)
5,6,-dimethyl-2-phenylimidazo[4,5-e]quinoxaline	1.9	>10	>10
6,7,-dimethyl-2-phenylimidazo[4,5-e]quinoxaline	4.3	88.4	>100

CONCLUSION

Thus, it will be appreciated that the compounds, methods
5 and pharmacological compositions of the present invention are
expected to modulate RTK and CTK activity and therefore to be
effective as therapeutic agents against RTK- and CTK-related
disorders.


Although certain embodiments and examples have been used
10 to describe the present invention, it will be apparent to those
skilled in the art that changes to the embodiments and examples
shown may be made without departing from the scope and spirit
of the invention.

Other embodiments are within the following claims.

CLAIMS

WHAT IS CLAIMED:

5 1. A compound having the chemical structure:



wherein,

A, B, and D are independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur;

10

The dotted line in the five-member ring signifies that either the A-B bond or the B-D bond is a double bond;

when A, B or D is oxygen or sulfur, R¹, R² or R³, respectively,
15 does not exist:

when A, B or D is nitrogen and said nitrogen is participating in a double bond, R^1 , R^2 or R^3 , respectively, does not exist:

20 When A, B or D is nitrogen and said nitrogen is not

participating in a double bond, R¹, R² or R³ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, halo, C-carboxy, O-carboxy, carbonyl, thiocarbonyl, C-amido, guanyl, sulfonyl and

5 trihalomethane- sulfonyl;

R⁴, R⁵, R⁶ and R⁷ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, 10 alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, N-sulfonamido, S-sulfonamido, trihalomethylsulfonamido, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, ureido, guanyl, 15 guanidino, amino and -NR¹⁰R¹¹ with the proviso that, when one of R⁵ or R⁶ is hydrogen, methyl or phenyl, the other cannot be any of hydrogen, methyl or phenyl;

R¹⁰ and R¹¹ are independently selected from the group consisting 20 of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, sulfonyl and, combined, a five- or six-member heteroalicyclic ring; and, a physiologically acceptable salt or a prodrug thereof.

2. The compound, salt or prodrug of claim 1 wherein:

25 A is nitrogen;

B is carbon;

the B-D bond is a double bond; and
D is nitrogen.

3. The compound, salt or prodrug of claim 2 wherein
5 R¹ is selected from the group consisting of hydrogen, alkyl,
cycloalkyl, aryl, carbonyl, C-carboxy and halo.

4. The compound, salt or prodrug of claim 3 wherein
R² is selected from the group consisting of hydrogen, alkyl,
10 cycloalkyl, trihalomethyl, aryl, halo, O-carboxy, hydroxy,
alkoxy, aryloxy, amino and -NR¹⁰R¹¹.

5. The compound, salt or prodrug of claim 4 wherein R⁴
and R⁷ are independently selected from the group consisting of
15 hydrogen, alkyl, cycloalkyl, alkoxy, aryloxy, C-carboxy,
hydroxy and halo.

6. The compound, salt or prodrug of claim 5 wherein R⁵ and
R⁶ are independently selected from the group consisting of
20 hydrogen, alkyl, cycloalkyl, alkoxy, aryl, aryloxy, heteroaryl,
heteroaliphatic, hydroxy and halo with the proviso that when
one of R⁵ or R⁶ is hydrogen, methyl or phenyl, the other is not
any of hydrogen, methyl or phenyl.

25 7. The compound, salt or prodrug of claim 1 wherein:

A is nitrogen;

the A-B bond is a double bond; and,

5 D is sulfur.

8. The compound, salt or prodrug of claim 7 wherein R², R⁴ and R⁷ are independently selected from the group consisting of hydrogen, alkyl or cycloalkyl.

10

9. The compound, salt or prodrug of claim 8 wherein R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy and aryloxy.

15

10. The compound, salt or prodrug of claim 1 wherein:

A is sulfur;

B and D are carbon; and,

the B-D bond is a double bond.

20

11. The compound, salt or prodrug of claim 10 wherein R² and R³ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, C-carboxy and C-amido.

25

12. The compound, salt or prodrug of claim 11 wherein R⁴ and R⁷ are independently selected from the group consisting

of alkyl, cycloalkyl, hydroxy, alkoxy, aryloxy and carbonyl.

13. The compound, salt or prodrug of claim 12 wherein R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl and heteroalicyclic with the proviso that when one of R⁵ or R⁶ is hydrogen, methyl or phenyl, the other is not any of hydrogen, methyl or phenyl.

14. A pharmacological composition of said compound, salt or prodrug of claim 1.

15. A method for treating or preventing a protein tyrosine kinase related disorder in an organism comprising administering to said organism a therapeutically effective amount of said pharmacological composition of claim 14.

16. The method of claim 15 wherein said protein tyrosine kinase related disorder is selected from the group consisting of an EGF related disorder, a PDGF related disorder, an IGF related disorder and a met related disorder.

17. The method of claim 15 wherein said protein tyrosine kinase related disorder is selected from the group consisting of blastoglioma, Kaposi's sarcoma, melanoma, lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma,

astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, small-cell lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.


5

18. The method of claim 15 wherein said protein tyrosine kinase related disorder is selected from the group consisting of arthritis, diabetic retinopathy, restenosis, hepatic cirrhosis, atherosclerosis, angiogenesis, glomerulonephritis, 10 diabetic nephropathy, thrombic microangiopathy syndromes, transplant rejection, autoimmune disease, diabetes and hyperimmune disorders.

19. The method of claim 15 wherein said organism is a 15 human.

20. A method for treating or preventing a protein tyrosine kinase related disorder in an organism comprising administering to said organism a therapeutically effective 20 amount of a pharmacological composition of a compound, its salts or its prodrugs, having the chemical structure

wherein:



A is selected from the group consisting of nitrogen, oxygen and sulfur;

5


B and D are selected from the group consisting of carbon and nitrogen with the proviso that, when B is nitrogen, D is not nitrogen and when D is nitrogen, B is not nitrogen;

10 The dotted line in the 5-member ring signifies that either the A-B or the B-D bond may be a double bond, it being understood that, when atom A is oxygen or sulfur or when atom B or D is nitrogen and said nitrogen is participating in a double bond, R¹, R² or R³, respectively, do not exist;

15

R¹ is selected from the group consisting of hydrogen, methyl, chloro and acetyl;

R² is selected from the group consisting of hydrogen, methyl, trifluoromethyl, hydroxy, 4-methylphenyl, HO-C(=O)-, CH₃OC(=O)-, H₂NC(=O)-, (CH₃CH₂)₂NC(=O)-, and;




5 R³ is selected from the group consisting of hydrogen, methyl and CH₃O-;

R⁴ is selected from the group consisting of hydrogen, CH₃O- and 4-methylphenyl;

10

R⁵ and R⁶ are the same and are selected from the group consisting of chloro,



R⁷ is selected from the group consisting of hydrogen and methyl.

15


21. The method of claim 20 wherein R⁵ and R⁶ are independently selected from the group consisting of hydrogen, methyl, phenyl and hydroxy.

AMENDED CLAIMS

[received by the International Bureau on 23 December 1998 (23.12.98);
new claims 22-33 and 21 added; remaining claims unchanged (13 pages)]

5

1. A compound having the chemical structure:



wherein,

A, B, and D are independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur;

10 The dotted line in the five-member ring signifies that either the A-B bond or the B-D bond is a double bond;

when A, B or D is oxygen or sulfur, R¹, R² or R³, respectively, does not exist;

15

when A, B or D is nitrogen and said nitrogen is participating in a double bond, R¹, R² or R³, respectively, does not exist;

When A, B or D is nitrogen and said nitrogen is not

20 participating in a double bond, R¹, R² or R³ is selected from

the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, halo, C-carboxy, O-carboxy, carbonyl, thiocarbonyl, C-amido, guanyl, sulfonyl and trihalomethane- sulfonyl;

5

R^4 , R^5 , R^6 and R^7 are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, 10 sulfanyl, sulfonyl, N-sulfonamido, S-sulfonamido, trihalomethylsulfonamido, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, ureido, guanyl, guanidino, amino and $-NR^{10}R^{11}$ with the proviso that, when one of 15 R^5 or R^6 is hydrogen, methyl or phenyl, the other cannot be any of hydrogen, methyl or phenyl;

R^{10} and R^{11} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, sulfonyl and, 20 combined, a five- or six-member heteroalicyclic ring; and, a physiologically acceptable salt or a prodrug thereof.

2. The compound, salt or prodrug of claim 1 wherein:

25 A is nitrogen;

B is carbon;
the B-D bond is a double bond; and
D is nitrogen.

5 3. The compound, salt or prodrug of claim 2 wherein
R¹ is selected from the group consisting of hydrogen, alkyl,
cycloalkyl, aryl, carbonyl, C-carboxy and halo.

10 4. The compound, salt or prodrug of claim 3 wherein
R² is selected from the group consisting of hydrogen, alkyl,
cycloalkyl, trihalomethyl, aryl, halo, O-carboxy, hydroxy,
alkoxy, aryloxy, amino and -NR¹⁰R¹¹.

15 5. The compound, salt or prodrug of claim 4 wherein R⁴
and R⁷ are independently selected from the group consisting of
hydrogen, alkyl, cycloalkyl, alkoxy, aryloxy, C-carboxy,
hydroxy and halo.

20 6. The compound, salt or prodrug of claim 5 wherein R⁵ and
R⁶ are independently selected from the group consisting of
hydrogen, alkyl, cycloalkyl, alkoxy, aryl, aryloxy, heteroaryl,
heteroaliphatic, hydroxy and halo with the proviso that when
one of R⁵ or R⁶ is hydrogen, methyl or phenyl, the other is not
any of hydrogen, methyl or phenyl.

7. The compound, salt or prodrug of claim 1 wherein:

A is nitrogen;

5

the A-B bond is a double bond; and,

D is sulfur.

10 8. The compound, salt or prodrug of claim 7 wherein R², R⁴ and R⁷ are independently selected from the group consisting of hydrogen, alkyl or cycloalkyl.

9. The compound, salt or prodrug of claim 8 wherein R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy and aryloxy.

10. The compound, salt or prodrug of claim 1 wherein:

20 A is sulfur;

B and D are carbon; and,

the B-D bond is a double bond.

11. The compound, salt or prodrug of claim 10 wherein R² and R³ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, C-carboxy and C-amido.

5 12. The compound, salt or prodrug of claim 11 wherein R⁴ and R⁷ are independently selected from the group consisting of alkyl, cycloalkyl, hydroxy, alkoxy, aryloxy and carbonyl.

10 13. The compound, salt or prodrug of claim 12 wherein R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl and heteroalicyclic with the proviso that when one of R⁵ or R⁶ is hydrogen, methyl or phenyl, the other is not any of hydrogen, methyl or phenyl.

15 14. A pharmacological composition of said compound, salt or prodrug of claim 1.

20 15. A method for treating or preventing a protein tyrosine kinase related disorder in an organism comprising administering to said organism a therapeutically effective amount of said pharmacological composition of claim 14.

25 16. The method of claim 15 wherein said protein tyrosine kinase related disorder is selected from the group consisting

of an EGF related disorder, a PDGF related disorder, an IGF related disorder and a met related disorder.


17. The method of claim 15 wherein said protein tyrosine kinase related disorder is selected from the group consisting of blastoglioma, Kaposi's sarcoma, melanoma, lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, small-cell lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, leukemia, lymphoma, 10 Hodgkin's disease and Burkitt's disease.

18. The method of claim 15 wherein said protein tyrosine kinase related disorder is selected from the group consisting of arthritis, diabetic retinopathy, restenosis, hepatic 15 cirrhosis, atherosclerosis, angiogenesis, glomerulonephritis, diabetic nephropathy, thrombic microangiopathy syndromes, transplant rejection, autoimmune disease, diabetes and hyperimmune disorders.

20

19. The method of claim 15 wherein said organism is a human.

20. A method for treating or preventing a protein tyrosine kinase related disorder in an organism comprising administering to said organism a therapeutically effective amount of a pharmacological composition of a compound, its
5 salts or its prodrugs, having the chemical structure:



wherein:

10 A is selected from the group consisting of nitrogen, oxygen and sulfur;


B and D are selected from the group consisting of carbon and nitrogen with the proviso that, when B is nitrogen, D is not nitrogen and when D is nitrogen, B is not nitrogen;

15

The dotted line in the 5-member ring signifies that either the A-B or the B-D bond may be a double bond, it being understood that, when atom A is oxygen or sulfur or when atom B or D is nitrogen and said nitrogen is participating in a double bond,
20 R¹, R² or R³, respectively, do not exist;

R^1 is selected from the group consisting of hydrogen, methyl, chloro and acetyl;

R^2 is selected from the group consisting of hydrogen, methyl,
5 trifluoromethyl, hydroxy, 4-methylphenyl, $\text{HO}(\text{C}=\text{O})^-$, $\text{CH}_3\text{OC}(\text{C}=\text{O})^-$,
 $\text{H}_2\text{NC}(\text{C}=\text{O})^-$, $(\text{CH}_3\text{CH}_2)_2\text{NC}(\text{C}=\text{O})^-$, and;



R^3 is selected from the group consisting of hydrogen, methyl and
CH₃O-;


10

R^4 is selected from the group consisting of hydrogen, CH₃O- and
4-methylphenyl;

15

R^5 and R^6 are the same and are selected from the group

consisting of chloro,



R^7 is selected from the group consisting of hydrogen and methyl.

21. The method of claim 20 wherein R⁵ and R⁶ are independently selected from the group consisting of hydrogen, methyl, phenyl and hydroxy.

5 22. The compound of claim 1 wherein B is selected from the group consisting of carbon, oxygen and sulfur.

23. The compound of claim 1, wherein:

A and D are nitrogen;

10 B is carbon;

the B-D bond is a double bond; and,

R¹ is selected from the group consisting of alkyl, cycloalkyl, aryl, carbonyl, C-carboxy and halo.

15 24. The compound, salt or prodrug of claim 23 wherein R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl, trihalomethyl, aryl, halo, O-carboxy, hydroxy, alkoxy, aryloxy, amino and -NR¹⁰R¹¹.

20 25. The compound, salt or prodrug of claim 24 wherein R⁴ and R⁷ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxy, aryloxy, C-carboxy, hydroxy and halo.

26. The compound, salt or prodrug of claim 25 wherein R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxy, aryl, aryloxy, heteroaryl, heteroaliphatic, hydroxy and halo with the proviso that when one of R⁵ or R⁶ is hydrogen, methyl or phenyl, the other is not any of hydrogen, methyl or phenyl.

27. A pharmacological composition comprising:
said compound, salt or prodrug of claim 23; and,
a physiologically acceptable carrier.

10

28. A method for treating or preventing a protein tyrosine kinase related disorder in an organism comprising administering to said organism a therapeutically effective amount of said pharmacological composition of claim 23.

15

29. The method of claim 28 wherein said protein tyrosine kinase related disorder is selected from the group consisting of an EGF related disorder, a PDGF related disorder, an IGF related disorder and a met related disorder.


20

30. The method of claim 28 wherein said protein tyrosine kinase related disorder is selected from the group consisting of blastoglioma, Kaposi's sarcoma, melanoma, lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, 25 astrocytoma, head cancer, neck cancer, bladder cancer, breast

cancer, small-cell lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.

5 31. The method of claim 28 wherein said protein tyrosine kinase related disorder is selected from the group consisting of arthritis, diabetic retinopathy, restenosis, hepatic cirrhosis, atherosclerosis, angiogenesis, glomerulonephritis, diabetic nephropathy, thrombic microangiopathy syndromes, 10 transplant rejection, autoimmune disease, diabetes and hyperimmune disorders.

15 32. A method for treating or preventing a protein tyrosine kinase related disorder in an organism comprising administering to said organism a therapeutically effective amount of a pharmacological composition of a compound, its salts or its prodrugs, having the chemical structure



20 wherein:

A is selected from the group consisting of nitrogen, oxygen and sulfur;

B is carbon;

5

D are selected from the group consisting of carbon and nitrogen;

The dotted line in the 5-member ring signifies that either the A-B or the B-D bond may be a double bond, it being understood 10 that, when A is oxygen or sulfur or when D is nitrogen and said nitrogen is participating in a double bond, R¹ or R³, respectively, do not exist;

R¹ is selected from the group consisting of methyl, chloro and 15 acetyl;

R² is selected from the group consisting of hydrogen, methyl, trifluoromethyl, hydroxy, 4-methylphenyl, HO₂C(=O) -, CH₃OC(=O) -, H₂NC(=O) -, (CH₃CH₂)₂NC(=O) -, and;




20

R³ is selected from the group consisting of hydrogen, methyl and CH₃O-;

R⁴ is selected from the group consisting of hydrogen, CH₃O- and 4-methylphenyl;

R⁵ and R⁶ are the same and are selected from the group
5 consisting of chloro,



R⁷ is selected from the group consisting of hydrogen and methyl.

33. The method of claim 20 wherein R⁵ and R⁶ are
10 independently selected from the group consisting of hydrogen,
methyl, phenyl and hydroxy.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/16232

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07D 403/02, 413/02, 411/02, 419/02, 417/02; A61K 31/495
US CL :544/345; 514/250

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 544/345; 514/250

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE STRUCTURE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,476,851 A (MYERS et al.) 19 December 1995, see examples 1-21.	1-21
X	US 5,116,843 A (MERTENS et al.) 26 May 1992, see especially examples 2 and 3.	1-21

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
A	Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
B	document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
C	earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
D	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
E	document referring to an oral disclosure, use, exhibition or other means		
F	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
25 SEPTEMBER 1998	26 OCT 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer MATTHEW V. GRUMBLING
Facsimile No. (703) 305-3230	Telephone No. (703) 308-1235